



Delayed impact of very low birth weight on glucose regulation: observational study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000327
Article Type:	Research
Date Submitted by the Author:	19-Aug-2011
Complete List of Authors:	Sato, Ryosuke; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II; Seirei Hamamatsu General Hospital, Department of Endocrinology and Metabolism Watanabe, Hiroshi; Hamamatsu University School of Medicine, Department of Clinical Pharmacology and Therapeutics Shirai, Kenji; Seirei Hamamatsu General Hospital, Department of Neonatology Ohki, Shigeru; Seirei Hamamatsu General Hospital, Department of Neonatology Genma, Rieko; Seirei Hamamatsu General Hospital, Department of Endocrinology and Metabolism Morita, Hiroshi; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II Inoue, Eisuke; Kitasato University, Department of Clinical Medicine (Biostatistics) Takeuchi, Masahiro; Kitasato University, Department of Clinical Medicine (Biostatistics) Maekawa, Masato; Hamamatsu University School of Medicine, Department of Laboratory Medicine Nakamura, Hirotoishi; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II
Primary Subject Heading:	Diabetes and endocrinology
Keywords:	Diabetes Mellitus, Very low birth weight (VLBW), Small for gestational age (SGA), Gender difference, Oral glucose tolerance test (OGTT)

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7 **Delayed impact of very low birth weight on glucose regulation:**
8
9
10 **observational study**
11

12 Ryosuke Sato,^{1,2} Hiroshi Watanabe,³ Kenji Shirai,⁴ Shigeru Ohki,⁴ Rieko Genma,²

15 Hiroshi Morita,¹ Eisuke Inoue,⁵ Masahiro Takeuchi,⁵ Masato Maekawa,⁶ Hirotoshi

17
18
19 Nakamura¹
20
21
22
23
24

25 **Address and Affiliations (position)**
26

27
28 ¹Department of Endocrinology and Metabolism, Division of Internal Medicine II, Hamamatsu
29 University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

30 Ryosuke Sato: Physician

31 Hiroshi Morita: Physician

32 Hirotoshi Nakamura: Professor
33
34

35
36
37 ²Department of Endocrinology and Metabolism, Seirei Hamamatsu General Hospital, 2-12-12,
38 Sumiyoshi, Naka-ku, Hamamatsu, 430-8558, Japan.

39 Ryosuke Sato: Physician

40 Rieko Genma: Physician
41
42
43

44
45 ³Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of
46 Medicine, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu,
47 431-3192, Japan.

48 Hiroshi Watanabe: Professor
49
50
51

52
53 ⁴Department of Neonatology, Seirei Hamamatsu General Hospital, 2-12-12, Sumiyoshi, Naka-ku,
54 Hamamatsu, 430-8558, Japan.

55 Kenji Shirai: neonatologist

56 Shigeru Ohki: neonatologist
57
58
59

60 ⁵Department of Clinical Medicine (Biostatistics), Kitasato University, 5-9-1, Shirokane, Minato-ku,

1
2
3
4
5
6 Tokyo, 108-8641, Japan.

7 Eisuke Inoue: statistician

8
9 Masahiro Takeuchi: Professor

10
11
12 ⁶Department of Laboratory Medicine, Hamamatsu University School of Medicine, 1-20-1,
13 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

14
15 Masato Maekawa: Professor

16
17
18
19 **Correspondence:** Ryosuke Sato, MD, Department of Endocrinology and Metabolism,

20
21
22 Division of Internal Medicine II, Hamamatsu University School of Medicine, 1-20-1,

23
24
25 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan. Tel: +81-53-435-2385; Fax:

26
27
28 +81-53-435-2386; E-mail: ryos@hama-med.ac.jp

29
30
31 Word counts for the abstract: 294

32
33
34 Word counts for the manuscript: 2200

35
36
37 The number of Bibliography: 27

38
39
40 The number of figures: 2

41
42
43 The number of tables: 3

44
45
46 **Keywords:** diabetes mellitus, very low birth weight (VLBW), small for gestational age

47
48
49 (SGA), gender difference, oral glucose tolerance test (OGTT)

ABSTRACT

Background: In recent decades, neonatal intensive care has been progressing dramatically and contributed to the improvement in survival rate of very low birth weight (VLBW; <1500g) infants. Although a lot of the first generation of VLBW infants are currently in their twenties or thirties, glucose regulation in their young adulthood is still uncertain.

Objectives: To investigate delayed impact of VLBW on glucose regulation in young adults.

Design: A cross-sectional, observational study included 111 young adults (42 men and 69 women; aged 19-30 years) born with VLBW between 1980 and 1990. Participants underwent standard 75-g oral glucose tolerance test (OGTT). Glucose and insulin levels during OGTT, the pancreatic beta cell function (insulinogenic index and homeostasis model of assessment for beta cell [HOMA- β]), and insulin resistance (homeostasis model of assessment for insulin resistance [HOMA-IR]) were evaluated.

Results: Of 111 young adults with VLBW, 21 subjects (19%) had glucose intolerance: 1 type 2 diabetes; 6 impaired glucose tolerance (IGT); 1 impaired fasting glycaemia (IFG); 13 non-diabetes/IGT/IFG with elevated 1-hour glucose levels (>8.6 mmol/l). In logistic regression analysis, male gender was an independent risk factor associated with glucose

1
2
3
4
5
6
7 intolerance (OR: 3.34; 95%CI: 1.08-10.3; p=0.036). Men had higher levels of glucose
8
9
10 (p<0.001) and lower levels of insulin (p=0.005) than women during OGTT. Pancreatic
11
12
13 beta cell function was lower in men (insulinogenic index: p=0.002; HOMA- β : p=0.001),
14
15
16 although no gender difference was found in insulin resistance (HOMA-IR: p=0.48). In
17
18
19 male subjects, logistic regression analysis showed that small for gestational age (SGA)
20
21
22 was an independent risk factor associated with glucose intolerance (OR: 33.3; 95%CI:
23
24
25 1.67-662.6; p=0.022).
26
27

28 **Conclusions:** 19% of individuals with VLBW already had glucose intolerance in young
29
30
31 adulthood, and male gender was a significant independent risk factor of glucose
32
33
34 intolerance. In male young adults with VLBW, SGA was associated with glucose
35
36
37 intolerance.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Neonatal intensive care has improved the survival rate for very low birth weight infants (VLBW; birth weight <1500g) in recent decades, and the first generation of VLBW infants have only recently reached young adulthood.
- Previous studies have shown the influence of low birth weight (birth weight <2500g) on type 2 diabetes and cardiovascular disease in later life.
- However, the glucose regulation in young adults with VLBW (<1500g) is still uncertain.

Key messages

- Of 111 young adults with VLBW in Asian population, 19% of individuals already had glucose intolerance.
- Male gender was a significant independent risk factor of glucose intolerance in young adults with VLBW.
- Small for gestational age (SGA) was associated with glucose intolerance particularly in male young adults with VLBW.

Strengths and limitations of this study

- This is a first study assessing the glucose regulation in young adults with VLBW in Asian population.
- Our study includes a relatively large number of young adults with VLBW.
- We could not obtain information regarding the postnatal growth pattern, which had been shown to be associated with later glucose intolerance in previous studies.

INTRODUCTION

In recent decades, progression of neonatal intensive care has dramatically increased the survival rate of very low birth weight (VLBW; birth weight <1500g) infants worldwide.¹ A lot of them have grown up into young adult (now in their twenties or thirties). To date, epidemiological studies have shown an association between low birth weight and type 2 diabetes and cardiovascular disease in later life.²⁻⁴ Fetal malnutrition in the gestational period, which prevents appropriate fetal growth in utero, is thought to provoke thrifty phenotype in premature babies. This phenotype is assumed to predispose them to subsequent metabolic disorders. For this reason, to foresee the later risk of type 2 diabetes is very crucial for VLBW infants. If prediction is possible, it would lead to early intervention in their lifestyle and subsequently contribute to prevention of type 2 diabetes.⁵⁻⁷

However, only a few studies have examined the association between VLBW and glucose regulation in young adulthood⁸ because the first generation of VLBW infants have only recently reached young adulthood. To clarify the delayed impact of VLBW on glucose regulation, we investigated glucose regulation in 111 young adults with VLBW by performing detailed oral glucose tolerance test (OGTT), which is useful for evaluation of early signs of glucose intolerance.

METHODS

Study Participants

The birth record database of Seirei Hamamatsu General Hospital (Hamamatsu, Japan) showed that 628 subjects were born with VLBW between 1980 and 1990, and were treated at a neonatal intensive care unit (**Figure 1**). VLBW infants were defined according to the World Health Organization (WHO) criteria: babies whose birth weight was less than 1500g. Out of the 628 subjects, 229 were excluded because of death or severe neurodevelopmental impairment. To the remaining 399 subjects, we sent letters which provided information regarding the study and requested their participation. Among the 399 letters, 98 were returned marked as address unknown (i.e. the remaining 301 letters were thought to reach their destinations). Consequently, 111 subjects (aged 19-30 years) participated in the present study. All participants were Japanese. Small for gestational age (SGA) status was determined according to standards by a study group of the Health Ministry in Japan: a birth weight below the 10th percentile for gestational age. The basal characteristics of participants at birth are summarized in **Table 1**.

Measurements

All participants underwent a standard 75-g OGTT after a ten-hour overnight fast.

1
2
3
4
5
6
7 Plasma glucose and serum insulin concentrations were examined at 0, 30, 60, 90, 120,
8
9
10 and 180 minutes during OGTT. Fasting glucose levels and 2-hour glucose levels were
11
12 used for diagnosing diabetes mellitus, impaired glucose tolerance (IGT), and impaired
13
14 fasting glycaemia (IFG) according to the WHO criteria. Since it has been shown that
15
16 1-hour plasma glucose concentration is associated with future risk of type 2 diabetes
17
18 and atherosclerosis, 1-hour plasma glucose above 8.6 mmol/l (155 mg/dl) was included
19
20 in glucose intolerance.^{9 10} Reactive hypoglycemia during OGTT was defined as the level
21
22 of plasma glucose less than 3.8 mmol/l which causes the response of counter-regulatory
23
24 hormone release.¹¹

25
26
27
28
29
30
31
32
33
34 We measured plasma glucose and serum insulin levels during OGTT with an
35
36 autoanalyzer JCA-BM2250 (JEOL, Tokyo, Japan). Plasma glucose was measured by
37
38 means of hexokinase method. The concentration of serum insulin was measured with
39
40 chemiluminescent enzyme immunoassay (CLIA). Fasting blood samples were also
41
42 drawn for other measurements; total cholesterol, high-density lipoprotein (HDL)
43
44 cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride, and creatinine.
45
46
47
48
49
50
51
52 Glycated haemoglobin A1c (HbA1c) was measured with high-performance liquid
53
54 chromatography (HPLC) method using an automated glycohaemoglobin analyzer
55
56 HLC-723G8 (Tosoh Bioscience, Tokyo, Japan). The values for HbA1c were converted
57
58
59
60

1
2
3
4
5
6
7 from Japanese Diabetes Society (JDS) values into National Glycohaemoglobin
8
9
10 Standardization Program (NGSP) equivalent values. NGSP equivalent values were
11
12
13 calculated with the formula: HbA1c (%) = JDS value (%) +0.4 (<http://www.jds.or.jp>).
14
15

16 17 18 19 **Calculations and Statistical analysis**

20
21
22 Pancreatic beta cell function was evaluated by both insulinogenic index and
23
24
25 homeostasis model of assessment for beta cell (HOMA- β).¹² Insulinogenic index, the
26
27
28 index of early-phase insulin secretion, was calculated as the ratio of the increment in
29
30
31 insulin concentration to the increment in glucose concentration ([30-min insulin
32
33
34 ($\mu\text{U/ml}$)–fasting insulin]/[30-min glucose (mmol/l) – fasting glucose]). HOMA- β was
35
36
37 calculated as follows: $20 \times \text{fasting insulin } (\mu\text{U/ml}) / [\text{fasting glucose (mmol/l)} - 3.5]$.
38
39
40 Insulin resistance was estimated by homeostasis model of assessment for insulin
41
42
43 resistance (HOMA-IR): $\text{fasting insulin } (\mu\text{U/ml}) \times \text{fasting glucose (mmol/l)} / 22.5$.¹² The
44
45
46 total amounts of glucose and insulin levels during OGTT were assessed by calculating
47
48
49 areas under the curve (AUC) with trapezoid rules. The estimated glomerular filtration
50
51
52 rate (eGFR) was calculated according to the Modification of Diet in Renal Disease
53
54
55 (MDRD) study equation.
56
57

58
59 Quantitative variables were expressed as mean and standard deviation (SD) or 95%
60

1
2
3
4
5
6
7 confidence interval (CI); categorical variables were presented as number and percentage.

8
9
10 Differences between groups were compared using the Student's t-test, the
11
12 Mann–Whitney U test, the Pearson's χ^2 test, or the repeated measure analysis of
13
14 variance (ANOVA) as appropriate. A p-value of less than 0.05 was defined as
15
16 statistically significant. All analyses were conducted using SAS software version 9.2
17
18 (SAS Institute, Cary, North Carolina, USA) and the statistical software R version 2.12.2
19
20 (http://www.r-project.org).
21
22
23
24
25
26
27
28
29
30

31 RESULTS

32
33
34 The basic characteristics of participants at study assessment are shown in **Table 1**. Of
35
36 111 young adults with VLBW, 21 subjects (19%) had glucose intolerance: one had type
37
38 2 diabetes; six had impaired glucose tolerance (IGT); one had impaired fasting
39
40 glycaemia (IFG); 13 non-diabetes/IGT/IFG subjects had elevated 1-hour glucose levels
41
42 (>8.6 mmol/l). Glucose intolerance was more frequent in men than women (26.2 % for
43
44 men vs 14.5 % for women). In the logistic regression analysis adjusted for family
45
46 history of diabetes within the second degree, BMI, gestational age, birth weight and
47
48 SGA/AGA (appropriate for gestational age), male gender was a statistically significant
49
50 independent factor associated with glucose intolerance (Odds ratio: 3.34; 95% CI:
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 1.08-10.3; $p= 0.036$). BMI at study assessment was also a significant independent risk
8
9
10 factor of glucose intolerance (**Table 2**).

16 **Gender difference**

17
18 As male gender was a significant independent risk factor of glucose intolerance, we
19
20 evaluated the differences in glucose regulation between men and women in the sample
21
22 group. **Figure 2** shows the glucose and insulin response during OGTT in men and
23
24 women. Men had significantly higher levels of glucose and lower levels of insulin
25
26 during OGTT than women by repeated measure ANOVA. $\text{Glucose}_{\text{AUC}}$ during OGTT
27
28 also tended to be higher in men (**Table 3**). As for the function of insulin secretion,
29
30 insulinogenic index and HOMA- β were significantly lower in men than in women.
31
32 $\text{Insulin}_{\text{AUC}}$ also showed a tendency to be lower in men. Reactive hypoglycemia during
33
34 OGTT tended to be frequent in men. The differences in the mean values of HbA1c and
35
36 HOMA-IR were not statistically significant. There were no significant gender
37
38 differences in gestational age ($p=0.15$), birth weight ($p=0.17$), age at study assessment
39
40 ($p=0.85$), BMI ($p=0.88$), the proportion of SGA ($p=0.76$), and that of family history of
41
42 diabetes within the second degree ($p=0.52$). The variables for glucose metabolism in
43
44 men and women are summarized in **Table 3**.

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 We evaluated the associations between gender and the variables of glucose metabolism
8
9
10 by multiple linear regression analysis. Adjustments were made for family history of
11
12 diabetes within the second degree, BMI, gestational age, birth weight, and SGA/AGA
13
14 (variables were logarithmically transformed before analysis). In this analysis, male
15
16 gender had inverse associations with HOMA- β (β : -0.336; 95% CI: -0.509 to -0.163; p <
17
18 0.001) and insulinogenic index (β : -0.195; 95% CI: -0.344 to -0.047; p =0.01).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Glucose_{AUC} during OGTT tended to be positively associated with male gender (β : 0.056;
95% CI: -0.0047 to 0.116; p =0.071).

In male subjects, after an adjustment for family history of diabetes, BMI, gestational age, and birth weight, the logistic regression analysis showed that SGA was a statistically significant independent factor associated with glucose intolerance (Odds ratio: 33.3; 95% CI: 1.67-662.6; p =0.022).

DISCUSSION

To the best of our knowledge, this is a first study assessing the glucose regulation in young adults with VLBW in Asian population. Our study has indicated that 19% of young adults with VLBW already had glucose intolerance: type 2 diabetes; IGT; IFG; and non-diabetes/IGT/IFG with high 1-hour plasma glucose level. A report from the

1
2
3
4
5
6
7 Japanese Ministry of Health, Welfare, and Labour in 2007 showed that of 204 general
8
9
10 young adults (aged 20-29 years), 2 individuals (0.98%) had high levels of HbA1c (more
11
12 than 6.0%; NGSP equivalent values), while 3.6% of young adults with VLBW had the
13
14
15 HbA1c values more than 6.0% in the present study. In a previous study, Hovi et al.
16
17 reported that VLBW infants in young adulthood had higher indexes of glucose
18
19 intolerance compared with term infants.⁸ On the other hand, a recent study in the
20
21
22 Netherlands showed that preterm birth was not associated with reduced insulin
23
24
25 sensitivity in young adulthood.¹³ Even though the glucose regulation of premature
26
27
28 infants in young adulthood is still controversial, our findings support the standpoint of
29
30
31 high prevalence of glucose intolerance in premature infants in young adulthood.
32
33
34
35

36
37 We have also found that male subjects had higher glucose levels during OGTT than
38
39
40 females. Previous studies in the general population showed that women had higher
41
42
43 postload glucose levels than men, which were explained by differences in body size.^{14 15}
44
45
46 During standard 75-g OGTT, men and women take the same amount of glucose, which
47
48
49 is thought to be high dosage for women relative to their body size. In our study,
50
51
52 however, men had significantly higher levels of both fasting and postload glucose
53
54
55 concentrations during OGTT. Moreover, male gender was associated with lower beta
56
57
58 cell function and the risk of glucose intolerance. These findings might indicate that men
59
60

1
2
3
4
5
6
7 with VLBW are more predisposed to diabetes than women; indeed, recent studies have
8
9
10 shown that male premature infants are more vulnerable than females.¹⁶⁻²¹ In particular,
11
12 the male sex is associated with various adverse outcomes including death,^{19 21}
13
14 respiratory dysfunction,¹⁶ intraventricular hemorrhage,¹⁸ autism spectrum,¹⁷ and
15
16 neurodevelopmental impairment.²⁰ Interestingly, in the present study, the mean value of
17
18 height (155cm) in women with VLBW is close to the average value of the Japanese
19
20 female population (158cm), whereas men with VLBW (164cm) were found to be
21
22 shorter compared to the Japanese male population (171cm) (average height data of
23
24 Japanese population were drawn from the report by the Ministry of Education, Culture,
25
26 Sports, Science, and Technology in Japan). In a previous study, young adults who had
27
28 been born SGA were shorter and had higher glucose levels than those with a normal
29
30 birth weight.²² Reduced final height might be long term consequences of intrauterine
31
32 retardation, which would also influence glucose regulation. Further investigation is
33
34 needed to clarify whether the influence of VLBW on physical growth is more
35
36 remarkable in male than female infants, and elucidate the relationship between physical
37
38 growth and glucose regulation.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Previous studies have shown that SGA itself is associated with glucose intolerance.²³

56
57
58 In our study, SGA was not significantly associated with glucose intolerance in total
59
60

1
2
3
4
5
6
7 subjects, but was associated in male subjects. The influence of SGA on glucose
8
9
10 regulation in young adults with VLBW might be stronger in male than females. It is
11
12 possible that this gender difference in glucose regulation is owing to the gender
13
14 difference in the strength of SGA effect.
15
16
17
18
19
20
21

22 **Strength and weakness of the study**

23
24
25 The major strength of our study is a well-characterized cohort of subjects with VLBW,
26
27 who are quite rare in the general population (approximately 0.5%). Our study includes a
28
29 relatively large number of young adults with VLBW, and the individuals with profound
30
31 complications were carefully excluded in the recruiting process. By this cautious
32
33 selection, 111 participants would represent the VLBW population spending common life
34
35 without disability in the general public, and it should make the findings of the study
36
37 more meaningful. In addition, as participants in the cohort were all Japanese, their racial
38
39 homogeneity made considerations of ethnic differences in glucose regulation
40
41 unnecessary. To date, the glucose regulation of Asian young adults with VLBW has
42
43 been uncertain. Our findings would be useful to clinicians and researchers, and
44
45 stimulate future large-scale prospective cohort studies in Asian population.
46
47
48
49
50
51
52
53
54
55
56
57
58

59 In the present study, we could not obtain information regarding the growth rate in
60

1
2
3
4
5
6
7 childhood of all participants. This is a major limitation of the study. The postnatal
8
9
10 growth pattern in infancy has been shown to be associated with later glucose
11
12 intolerance.²⁴⁻²⁷ The clinical records of participants were written 20 to 30 years ago, and
13
14
15 some of them were no longer preserved. Additionally, maternal factors such as advanced
16
17
18 age, smoking, gestational diabetes, and perinatal complications were not available in the
19
20
21 present study. These factors might have affected fetal malnutrition and subsequently led
22
23
24 to VLBW.
25
26
27
28
29
30

31 **Future Perspective**

32
33
34 As neonatal intensive care is making steady progress, an increasing number of young
35
36
37 adults with VLBW worldwide will face a greater variety of health problems. Clinician
38
39
40 should be aware of the risk of glucose intolerance in young adults with VLBW, and
41
42
43 follow up them for a longer period of time. It may be worthwhile for them to check their
44
45
46 glucose metabolism with OGTT in their twenties or thirties, which would lead to early
47
48
49 intervention in their lifestyle and subsequently contribute to prevention of type 2
50
51
52 diabetes and cardiovascular disease.⁵⁻⁷ In the present study, we have found that male
53
54
55 gender was a significant independent risk factor of glucose intolerance in young adults
56
57
58 with VLBW. In addition to the gender difference, future studies are required to focus on
59
60

1
2
3
4
5
6
7 the factors affecting the glucose metabolism in VLBW infants.
8
9

10
11
12 **Acknowledgment:** The authors thank all the participants who participated in this study;
13
14
15
16 the pediatricians who have treated the participants in their neonatal periods; the
17
18
19 colleagues who made a great contribution to the study as clinical research coordinators:
20
21
22 Masahiro Asano, Kikuko Tejima, Emiko Morita, Mari Suzuki, Kaoru Kikuchi, and
23
24
25 Chieko Suzuki; the colleagues who played vital roles by excellent technical assistance:
26
27
28 Hiromi Kajima, Takako Akiyama, and Masato Shouji; and Keisuke Ishii and Gregory
29
30
31 O'Dowd for encouraging advice on the present study.
32
33
34
35
36

37
38 **Contributors:** RS and HW drafted the paper. RS conceived the study. RS and KS
39
40
41 developed the idea. RS, HW, KS, SO, RG, MM, and HN were involved in study design.
42
43
44 RS and KS participated in data acquisition. RS, HW, HM, EI, MT, and MM were
45
46
47 engaged in data analysis.
48
49

50
51 **Funding:** This study was partly supported by grants from the Japan Society for the
52
53
54 Promotion of Science (21390180) and from the Ministry of Health, Labour and Welfare
55
56
57 in Japan (H23-Cardiovascular disease and Diabetes-011).
58

59 **Competing Interest:** None.
60

1
2
3
4
5
6
7 **Ethical approval:** The study was approved by the ethical committee of Seirei
8
9
10 Hamamatsu General Hospital. All participants provided written informed consent to
11
12 participate in the study.
13
14

15
16 **Data sharing statement:** Data will not be publically accessible. However, interested
17
18 individuals may contact the authors.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Field DJ, Dorling JS, Manktelow BN, Draper ES. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. *BMJ* 2008;336(7655):1221-3.
2. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. *Lancet* 1993;341(8850):938-41.
3. Kaijser M, Bonamy AK, Akre O, Cnattingius S, Granath F, Norman M, et al. Perinatal risk factors for diabetes in later life. *Diabetes* 2009;58(3):523-6.
4. Whincup PH, Kaye SJ, Owen CG, Huxley R, Cook DG, Anazawa S, et al. Birth weight and risk of type 2 diabetes: a systematic review. *JAMA* 2008;300(24):2886-97.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346(6):393-403.
6. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. *Diabetologia* 1991;34(12):891-8.
7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344(18):1343-50.
8. Hovi P, Andersson S, Eriksson JG, Jarvenpaa AL, Strang-Karlsson S, Makitie O, et al. Glucose regulation in young adults with very low birth weight. *N Engl J Med* 2007;356(20):2053-63.
9. Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. *Diabetes Care* 2008;31(8):1650-5.
10. Succurro E, Marini MA, Arturi F, Grembiale A, Lugara M, Andreozzi F, et al. Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. *Atherosclerosis* 2009;207(1):245-9.
11. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. *Diabetes Care* 2005;28(12):2948-61.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.

- 1
2
3
4
5
6 Homeostasis model assessment: insulin resistance and beta-cell function from
7 fasting plasma glucose and insulin concentrations in man. *Diabetologia*
8 1985;28(7):412-9.
- 10
11 13. Willemsen RH, Leunissen RW, Stijnen T, Hokken-Koelega AC. Prematurity is not
12 associated with reduced insulin sensitivity in adulthood. *J Clin Endocrinol*
13 *Metab* 2009;94(5):1695-700.
- 14
15 14. Faerch K, Borch-Johnsen K, Vaag A, Jorgensen T, Witte DR. Sex differences in
16 glucose levels: a consequence of physiology or methodological convenience?
17 The Inter99 study. *Diabetologia* 2010;53(5):858-65.
- 18
19 15. Sicree RA, Zimmet PZ, Dunstan DW, Cameron AJ, Welborn TA, Shaw JE.
20 Differences in height explain gender differences in the response to the oral
21 glucose tolerance test- the AusDiab study. *Diabet Med* 2008;25(3):296-302.
- 22
23 16. Henderson-Smart DJ, Hutchinson JL, Donoghue DA, Evans NJ, Simpson JM,
24 Wright I. Prenatal predictors of chronic lung disease in very preterm infants.
25 *Arch Dis Child Fetal Neonatal Ed* 2006;91(1):F40-5.
- 26
27 17. Johnson S, Hollis C, Kochhar P, Hennessy E, Wolke D, Marlow N. Autism spectrum
28 disorders in extremely preterm children. *J Pediatr* 2010;156(4):525-31 e2.
- 29
30 18. Mohamed MA, Aly H. Male gender is associated with intraventricular hemorrhage.
31 *Pediatrics* 2010;125(2):e333-9.
- 32
33 19. Morse SB, Wu SS, Ma C, Ariet M, Resnick M, Roth J. Racial and gender
34 differences in the viability of extremely low birth weight infants: a
35 population-based study. *Pediatrics* 2006;117(1):e106-12.
- 36
37 20. Spinillo A, Montanari L, Gardella B, Roccio M, Stronati M, Fazzi E. Infant sex,
38 obstetric risk factors, and 2-year neurodevelopmental outcome among preterm
39 infants. *Dev Med Child Neurol* 2009;51(7):518-25.
- 40
41 21. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD. Intensive care for extreme
42 prematurity--moving beyond gestational age. *N Engl J Med*
43 2008;358(16):1672-81.
- 44
45 22. Leger J, Levy-Marchal C, Bloch J, Pinet A, Chevenne D, Porquet D, et al. Reduced
46 final height and indications for insulin resistance in 20 year olds born small for
47 gestational age: regional cohort study. *BMJ* 1997;315(7104):341-7.
- 48
49 23. Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short
50 stature and beyond. *Endocr Rev* 2007;28(2):219-51.
- 51
52 24. Crowther NJ, Cameron N, Trusler J, Toman M, Norris SA, Gray IP. Influence of
53 catch-up growth on glucose tolerance and beta-cell function in 7-year-old
54 children: results from the birth to twenty study. *Pediatrics*
55
56
57
58
59
60

- 1
2
3
4
5
6 2008;121(6):e1715-22.
- 7
8 25. Eriksson JG, Osmond C, Kajantie E, Forsen TJ, Barker DJ. Patterns of growth
9 among children who later develop type 2 diabetes or its risk factors.
10 *Diabetologia* 2006;49(12):2853-8.
11
- 12 26. Finken MJ, Keijzer-Veen MG, Dekker FW, Frolich M, Hille ET, Romijn JA, et al.
13 Preterm birth and later insulin resistance: effects of birth weight and postnatal
14 growth in a population based longitudinal study from birth into adult life.
15 *Diabetologia* 2006;49(3):478-85.
16
- 17 27. Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega A. Timing and tempo of
18 first-year rapid growth in relation to cardiovascular and metabolic risk profile in
19 early adulthood. *JAMA* 2009;301(21):2234-42.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Clinical characteristics of young adults with very low birth weight (VLBW) at birth and at study assessment

	Total (n=111)	Men (n=42)	Women (n=69)
At birth			
Gestational Age (wk)	29.7 (3.1)	29.2 (3.1)	30.0 (3.2)
Weight (g)	1152 (235)	1116 (233)	1174 (235)
ELBW	33 (29.7)	16 (38.1)	17 (24.6)
SGA*	39 (35.1)	14 (33.3)	25 (36.2)
Birth from multiple pregnancy	18 (16.2)	9 (21.4)	9 (13.0)
At study assessment			
Age (yr)	24.8 (3.0)	24.7 (3.4)	24.9 (2.9)
Family history of diabetes	22 (19.8)	7 (16.7)	15 (21.7)
Height (m)	1.58 (0.07)	1.64 (0.06)	1.55 (0.06)
Body Weight (kg)	52.3 (10.1)	54.9 (8.8)	50.7 (10.5)
BMI (kg/m ²)	20.9 (3.8)	20.5 (2.9)	21.1 (4.2)
Blood pressure (mmHg)			
Systolic	118 (16)	121 (17)	116 (14)
Diastolic	70 (11)	69 (12)	70 (10)
Cholesterol (mg/dl)			
Total	184.8 (31.3)	192.5 (38.0)	180.1 (25.7)
Low-density lipoprotein	104.3 (28.4)	112.1 (35.5)	99.5 (22)
High- density lipoprotein	65.7 (13.3)	64.1 (13.9)	66.6 (13.0)
Triglycerides (mg/dl)	81.8 (72.2)	96.2 (106.7)	73.0 (36.9)
Renal function			
Creatinine (mg/dl)	0.66 (0.13)	0.79 (0.11)	0.58 (0.81)
eGFR (ml/min/1.73 m ²)†	104.6 (18.4)	103.0 (17.7)	105.6 (18.9)

ELBW=Extremely low birth weight (<1000g); SGA=Small for gestational age; BMI=body mass index; eGFR=estimated glomerular filtration rate.

Data are expressed as mean (SD) or number (%).

* Determined by a birth weight below the 10th percentile for gestational age according to standards defined by a study group of the Health Ministry in Japan.

† Calculated according to the Modification of Diet in Renal Disease (MDRD) study equation.

Table 2. Correlated factors for glucose intolerance* in young adults with very low birth weight (VLBW) assessed by logistic regression analyses

Variable	Odds Ratio	95% CI	P-value
Gender (Male)	3.34	1.08 - 10.3	0.036
Factors at birth			
Gestational Age (wk)	0.77	0.53 - 1.12	0.165
Weight (g)	1.00	1.00 - 1.01	0.085
SGA	2.56	0.37 - 17.5	0.340
Factors at study assessment			
Family history of diabetes	1.92	0.49 - 7.57	0.353
BMI (kg/m ²)	1.29	1.11 - 1.49	0.001

SGA=Small for gestational age; BMI=body mass index.

*Glucose intolerance includes Diabetes, IGT (impaired glucose tolerance), IFG (impaired fasting glycaemia), and Non-diabetes/IGT/IFG with elevated 1-hour glucose levels (> 8.6mmol/l).

Table 3. Gender differences in glucose regulation in young adults with very low birth weight (VLBW)

	Men (n=42)	Women (n=69)	P-value
Glucose intolerance	11 (26.2)	10 (14.5)	0.13
Diabetes	0	1	
IGT	2	4	
IFG	1	0	
Non-diabetes/IGT/IFG with elevated 1-hour glucose levels*	8	5	
HbA1c (%)	5.39 (5.31 - 5.47)	5.39 (5.31 - 5.47)	0.64
HOMA- β	72.5 (59.0 - 86.0)	103 (87.2 - 119.6)	0.001
HOMA-IR	1.4 (1.14 - 1.69)	1.6 (1.29 - 1.90)	0.48
Variable during OGTT			
Insulinogenic Index	1.1 (0.64 - 1.60)	1.4 (1.18 - 1.71)	0.002
Glucose _{AUC} (mmol/l \times hr)	18.8 (17.9 - 19.7)	18.2 (17.3 - 19.0)	0.089
Insulin _{AUC} (μ U/ml \times hr)	135.3 (98.7 - 171.9)	145.1 (121.7 - 168.6)	0.052
Reactive hypoglycemia	17 (40)	17 (25)	0.079

IGT=impaired glucose tolerance; IFG=impaired fasting glycaemia; HOMA- β =homeostasis model of assessment for beta cell; HOMA-IR=homeostasis model of assessment for insulin resistance.

Data are expressed as mean (95% CI) or number (%).

*Defined as 1-hour glucose levels > 8.6mmol/l.

Figure Legends

Figure 1. Flow of participants through the study

(There is no figure legend in Figure 1.)

Figure 2. The gender differences of glucose and insulin levels during OGTT in young adults with very low birth weight (VLBW)

Male subjects had significantly higher levels of glucose and lower levels of insulin during OGTT than female subjects ($p < 0.001$ for glucose and $p = 0.005$ for insulin by repeated measure ANOVA).

The numerical data of Figure 2.

Male (n=42)

	0 (min)	30	60	90	120	180
Plasma glucose (mg/dl)	5.208 (0.3695)	8.579 (1.272)	7.167 (1.824)	6.262 (1.523)	5.749 (1.102)	4.360 (1.205)
Insulin (microU/ml)	6.057 (3.519)	64.95 (64.53)	53.70 (47.86)	53.27 (49.61)	49.84 (50.66)	20.94 (24.37)

Female (n=69)

	0 (min)	30	60	90	120	180
Plasma glucose (mg/dl)	4.930 (0.4266)	7.529 (1.460)	6.596 (1.946)	6.178 (1.541)	5.829 (1.487)	4.881 (1.121)
Insulin (microU/ml)	7.090 (5.107)	66.22 (42.62)	57.09 (51.97)	54.95 (44.39)	51.11 (39.85)	31.82 (28.03)

Data are expressed as mean (SD).

Figure 1. Flow of Participants through the study






Figure 2. The gender differences of glucose and insulin levels during OGTT in young adults with very low birth weight (VLBW)



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	n/a
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11, 13
		(b) Describe any methods used to examine subgroups and interactions	13
		(c) Explain how missing data were addressed	n/a
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	n/a
Outcome data	15*	Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-13
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13
Discussion			
Key results	18	Summarise key results with reference to study objectives	13-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



A cross-sectional study of glucose regulation in young adults with very low birth weight: impact of male gender on hyperglycemia

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000327.R1
Article Type:	Research
Date Submitted by the Author:	24-Nov-2011
Complete List of Authors:	Sato, Ryosuke; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II; Seirei Hamamatsu General Hospital, Department of Endocrinology and Metabolism Watanabe, Hiroshi; Hamamatsu University School of Medicine, Department of Clinical Pharmacology and Therapeutics Shirai, Kenji; Seirei Hamamatsu General Hospital, Department of Neonatology Ohki, Shigeru; Seirei Hamamatsu General Hospital, Department of Neonatology Genma, Rieko; Seirei Hamamatsu General Hospital, Department of Endocrinology and Metabolism Morita, Hiroshi; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II Inoue, Eisuke; Kitasato University, Department of Clinical Medicine (Biostatics) Takeuchi, Masahiro; Kitasato University, Department of Clinical Medicine (Biostatics) Maekawa, Masato; Hamamatsu University School of Medicine, Department of Laboratory Medicine Nakamura, Hirotohi; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Paediatrics, Cardiovascular medicine
Keywords:	Diabetes Mellitus, Very low birth weight (VLBW), Small for gestational age (SGA), Gender difference, Oral glucose tolerance test (OGTT), hyperglycemia

1
2
3
4
5
6 **A cross-sectional study of glucose regulation in young adults with very**
7
8
9 **low birth weight: impact of male gender on hyperglycemia**
10
11
12
13

14 Ryosuke Sato,^{1,2} Hiroshi Watanabe,³ Kenji Shirai,⁴ Shigeru Ohki,⁴ Rieko Genma,²
15
16

17 Hiroshi Morita,¹ Eisuke Inoue,⁵ Masahiro Takeuchi,⁵ Masato Maekawa,⁶ Hirotoishi
18
19

20 Nakamura¹
21
22
23
24
25

26 **Address and Affiliations (position)**
27

28 ¹Department of Endocrinology and Metabolism, Division of Internal Medicine II, Hamamatsu
29 University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

30 Ryosuke Sato: Physician
31

32 Hiroshi Morita: Physician
33

34 Hirotoishi Nakamura: Professor
35
36

37 ²Department of Endocrinology and Metabolism, Seirei Hamamatsu General Hospital, 2-12-12,
38 Sumiyoshi, Naka-ku, Hamamatsu, 430-8558, Japan.

39 Ryosuke Sato: Physician
40

41 Rieko Genma: Physician
42
43

44 ³Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of
45 Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

46 Hiroshi Watanabe: Professor
47
48
49

50 ⁴Department of Neonatology, Seirei Hamamatsu General Hospital, 2-12-12, Sumiyoshi, Naka-ku,
51 Hamamatsu, 430-8558, Japan.

52 Kenji Shirai: Neonatologist
53

54 Shigeru Ohki: Neonatologist
55
56
57
58
59
60

⁵Department of Clinical Medicine (Biostatistics), Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo, 108-8641, Japan.

Eisuke Inoue: Statistician

Masahiro Takeuchi: Professor

⁶Department of Laboratory Medicine, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

Masato Maekawa: Professor

Correspondence: Ryosuke Sato, MD, Department of Endocrinology and Metabolism,

Division of Internal Medicine II, Hamamatsu University School of Medicine, 1-20-1,

Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan. Tel: +81-53-435-2385; Fax:

+81-53-435-2386; E-mail: ryos@hama-med.ac.jp

Word counts for the abstract: 298

Word counts for the manuscript: 2428

The number of Bibliography: 35

The number of figures: 2

The number of tables: 3

Keywords: diabetes mellitus, very low birth weight (VLBW), small for gestational age

(SGA), gender difference, oral glucose tolerance test (OGTT)

ABSTRACT

Objectives: To investigate glucose regulation in young adults with very low birth weight (VLBW; <1500g) in an Asian population.

Design: Cross-sectional, observational study.

Setting: A general hospital in Hamamatsu, Japan.

Participants: 111 young adults (42 men and 69 women; aged 19-30 years) born with VLBW between 1980 and 1990. Participants underwent standard 75-g oral glucose tolerance test (OGTT).

Primary and secondary outcome measures: The primary outcomes were glucose and insulin levels during OGTT, and risk factors for a category of hyperglycemia defined as follows: diabetes mellitus; impaired glucose tolerance (IGT); impaired fasting glycemia (IFG); and non-diabetes/IGT/IFG with elevated 1-hour glucose levels (>8.6 mmol/l). The secondary outcomes were the pancreatic beta cell function (insulinogenic index and homeostasis model of assessment for beta cell [HOMA- β]), and insulin resistance (homeostasis model of assessment for insulin resistance [HOMA-IR]).

Results: Of 111 young adults with VLBW, 21 subjects (19%) had hyperglycemia: 1 had type 2 diabetes; 6 had IGT; 1 had IFG; and 13 had non-diabetes/IGT/IFG with elevated 1-hour glucose levels. In logistic regression analysis, male gender was an independent

1
2
3
4
5
6 risk factor associated with hyperglycemia (OR: 3.34; 95%CI: 1.08-10.3; p=0.036). Male
7
8
9 subjects had significantly higher levels of glucose and lower levels of insulin during
10
11
12 OGTT than female subjects (p<0.001 for glucose and p=0.005 for insulin by repeated
13
14
15 measure ANOVA). Pancreatic beta cell function was lower in men (insulinogenic index:
16
17
18 p=0.002; HOMA- β : p=0.001), although no gender difference was found in insulin
19
20
21 resistance (HOMA-IR: p=0.477). In male subjects, logistic regression analysis showed
22
23
24 that small for gestational age (SGA) was an independent risk factor associated with
25
26
27 hyperglycemia (OR: 33.3; 95%CI: 1.67-662.6; p=0.022).

28
29 **Conclusions:** 19% of individuals with VLBW already had hyperglycemia in young
30
31
32 adulthood, and male gender was a significant independent risk factor of hyperglycemia.
33
34
35 In male young adults with VLBW, SGA was associated with hyperglycemia.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Neonatal intensive care has improved the survival rate for very low birth weight infants (VLBW; birth weight <1500g) in recent decades, and the first generation of VLBW infants have only recently reached young adulthood.
- Only a few studies have shown that VLBW (or preterm) is associated with glucose intolerance in Caucasian young adults, while glucose regulation in Asian young adults with VLBW is still uncertain.
- The present study investigated glucose regulation in young adults with VLBW in an Asian population, and determined the factors associated with hyperglycemia.

Key messages

- Of 111 young adults with VLBW, 19% of individuals already had hyperglycemia (type 2 diabetes, IGT, IFG, and non-diabetes/IGT/IFG with elevated 1-hour glucose levels).
- Male gender was a significant independent risk factor of hyperglycemia in young adults with VLBW.
- Small for gestational age (SGA) was associated with hyperglycemia particularly in

1
2
3
4
5
6 male young adults with VLBW.
7
8
9

10 11 **Strengths and limitations of this study**

- 14 ■ This is the first study assessing the glucose regulation in young adults with VLBW
15
16 in an Asian population.
17
18
- 20 ■ This study does not provide information on postnatal growth patterns, which have
21
22 been shown to be associated with later hyperglycemia in previous studies.
23
24
- 26 ■ The study design with no control subjects makes it impossible to address the
27
28 delayed impact of VLBW itself on glucose regulation.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

In recent decades, progression of neonatal intensive care has dramatically increased the survival rate of very low birth weight (VLBW; birth weight <1500g) infants worldwide.¹ A lot of them have grown up into young adult (now in their twenties or thirties). To date, epidemiological studies have shown an association between low birth weight and type 2 diabetes and cardiovascular disease in later life.²⁻⁴ Fetal malnutrition in the gestational period, which prevents appropriate fetal growth in utero, is thought to provoke thrifty phenotype in premature babies. This phenotype is assumed to predispose them to subsequent metabolic disorders. For this reason, to foresee the later risk of type 2 diabetes is very crucial for VLBW infants, which would lead to prevention of type 2 diabetes by early intervention in their lifestyle.⁵⁻⁷

The first generation of VLBW infants have only recently reached young adulthood. A few studies have shown that VLBW (or preterm) is associated with glucose intolerance in young adulthood in Caucasian populations,^{8,9} while the glucose regulation in Asian young adults with VLBW remains uncertain. To clarify the characteristics of glucose metabolism in young adults with VLBW in an Asian population, we investigated glucose regulation in 111 young adults with VLBW by performing detailed oral glucose tolerance test (OGTT), which is useful for evaluation of early signs of glucose

1
2
3
4
5
6 intolerance.

7 8 9 10 11 12 **METHODS**

13 14 15 **Study Participants**

16
17 The birth record database of Seirei Hamamatsu General Hospital (Hamamatsu, Japan)
18 showed that 628 subjects were born with VLBW between 1980 and 1990, and were
19 treated at a neonatal intensive care unit (**Figure 1**). VLBW infants were defined
20 according to the World Health Organization (WHO) criteria: babies whose birth weight
21 was less than 1500g. Out of the 628 subjects, 229 were excluded because of death
22 (n=132) or severe neurodevelopmental impairment (n=97). To the remaining 399
23 subjects, we sent letters which provided information regarding the study and requested
24 their participation. Among the 399 letters, 98 were returned marked as address unknown
25 (i.e. the remaining 301 letters were thought to reach their destinations). Consequently,
26 111 subjects (aged 19-30 years) participated in the present study. All participants were
27 Japanese. Small for gestational age (SGA) status was determined according to standards
28 by a study group of the Health Ministry in Japan: a birth weight below the 10th
29 percentile for gestational age.¹⁰ The basal characteristics of participants at birth are
30 summarized in **Table 1**.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Measurements

All participants underwent a standard 75-g OGTT after a ten-hour overnight fast.

Plasma glucose and serum insulin concentrations were examined at 0, 30, 60, 90, 120, and 180 minutes during OGTT. Fasting glucose levels and 2-hour glucose levels were used for diagnosing diabetes mellitus, impaired glucose tolerance (IGT), and impaired fasting glycaemia (IFG) according to the WHO criteria.¹¹ Since it has been shown that 1-hour plasma glucose concentration is associated with future risk of type 2 diabetes and atherosclerosis, 1-hour plasma glucose above 8.6 mmol/l (155 mg/dl) was included as a category of hyperglycemia.^{12 13} Reactive hypoglycemia during OGTT was defined as the level of plasma glucose less than 3.8 mmol/l which causes the response of counter-regulatory hormone release.¹⁴

We measured plasma glucose and serum insulin levels during OGTT with an autoanalyzer JCA-BM2250 (JEOL, Tokyo, Japan). Plasma glucose was measured by means of hexokinase method. The concentration of serum insulin was measured with chemiluminescent enzyme immunoassay (CLIA). Fasting blood samples were also drawn for other measurements; total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride, and creatinine.

1
2
3
4
5
6 Glycated haemoglobin A1c (HbA1c) was measured with high-performance liquid
7
8
9 chromatography (HPLC) method using an automated glycohaemoglobin analyzer
10
11
12 HLC-723G8 (Tosoh Bioscience, Tokyo, Japan). The values for HbA1c were converted
13
14
15 from Japanese Diabetes Society (JDS) values into National Glycohaemoglobin
16
17
18 Standardization Program (NGSP) equivalent values. NGSP equivalent values were
19
20
21 calculated with the formula: $\text{HbA1c (\%)} = \text{JDS value (\%)} + 0.4$.¹⁵
22
23
24
25

26 **Calculations and Statistical analysis**

27
28
29 Pancreatic beta cell function was evaluated by both insulinogenic index and
30
31
32 homeostasis model of assessment for beta cell (HOMA- β).¹⁶ Insulinogenic index, the
33
34
35 index of early-phase insulin secretion, was calculated as the ratio of the increment in
36
37
38 insulin concentration to the increment in glucose concentration ($[\text{30-min insulin}$
39
40
41 $(\mu\text{U/ml}) - \text{fasting insulin}] / [\text{30-min glucose (mmol/l)} - \text{fasting glucose}]$). HOMA- β was
42
43
44 calculated as follows: $20 \times \text{fasting insulin } (\mu\text{U/ml}) / [\text{fasting glucose (mmol/l)} - 3.5]$.
45
46
47 Insulin resistance was estimated by homeostasis model of assessment for insulin
48
49
50 resistance (HOMA-IR): $\text{fasting insulin } (\mu\text{U/ml}) \times \text{fasting glucose (mmol/l)} / 22.5$.¹⁶ The
51
52
53 total amounts of glucose and insulin levels during OGTT were assessed by calculating
54
55
56 areas under the curve (AUC) with trapezoid rules. The estimated glomerular filtration
57
58
59
60

1
2
3
4
5
6 rate (eGFR) was calculated according to the following formula, as recommended by the
7
8
9 Japanese Society of Nephrology: $eGFR \text{ (ml/min/1.73m}^2\text{)} = 194 \times \text{Cre}^{-1.094} \times \text{Age}^{-0.287} (\times$
10
11
12 0.739 if the subject is a woman).¹⁷
13

14
15 Quantitative variables were expressed as mean and standard deviation (SD) or 95%
16
17 confidence interval (CI); categorical variables were presented as number and percentage.
18
19 Differences between groups were compared using the Student's t-test, the
20
21 Mann–Whitney U test, the Pearson's χ^2 test, or the repeated measure analysis of
22
23 variance (ANOVA) as appropriate. The data on insulin levels during OGTT were
24
25 logarithmically transformed before the repeated measure ANOVA. Logistic regression
26
27 analysis which included gender, family history of diabetes within the second degree,
28
29 BMI, gestational age, birth weight, and SGA/AGA (appropriate for gestational age) was
30
31 performed to estimate odds ratios for the category of hyperglycemia. For the further
32
33 investigation into glucose regulation, multiple linear regression analysis was conducted.
34
35 Gender, family history of diabetes, BMI, gestational age, birth weight, and SGA/AGA
36
37 were included in the model. The data on HOMA- β , HOMA-IR, Insulinogenic Index,
38
39 and $\text{Glucose}_{\text{AUC}}$ were logarithmically transformed before analysis to meet the
40
41 assumptions of normality. A p-value of less than 0.05 was defined as statistically
42
43 significant. All analyses were conducted using SAS software version 9.2 (SAS Institute,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Cary, North Carolina, USA) and the statistical software R version 2.12.2
7
8
9 (http://www.r-project.org).
10

11 12 13 14 15 **RESULTS**

16
17 The basic characteristics of participants at study assessment are shown in **Table 1**. Of
18
19 111 young adults with VLBW, 21 subjects (19%) had hyperglycemia: one had type 2
20
21 diabetes; six had impaired glucose tolerance (IGT); one had impaired fasting glycaemia
22
23 (IFG); 13 non-diabetes/IGT/IFG subjects had elevated 1-hour glucose levels (>8.6
24
25 mmol/l). Hyperglycemia was more frequent in men than women (26.2 % for men vs
26
27 14.5 % for women). In the logistic regression analysis adjusted for family history of
28
29 diabetes within the second degree, BMI, gestational age, birth weight and SGA/AGA,
30
31 male gender was a statistically significant independent factor associated with
32
33 hyperglycemia (Odds ratio: 3.34; 95% CI: 1.08-10.3; p= 0.036). BMI at study
34
35 assessment was also associated with hyperglycemia (**Table 2**).
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Gender difference**

50
51 As male gender was a significant independent risk factor of hyperglycemia, we
52
53 evaluated the differences in glucose regulation between men and women in the sample
54
55
56
57
58
59
60

1
2
3
4
5
6 group. **Figure 2** shows the glucose and insulin response during OGTT in men and
7
8
9 women. Male subjects had significantly higher levels of glucose during OGTT than
10
11 female subjects ($p < 0.001$ by repeated measure ANOVA). In terms of insulin levels,
12
13 male subjects had lower levels of insulin during OGTT than female subjects ($p = 0.005$
14
15 by repeated measure ANOVA). Glucose_{AUC} during OGTT tended to be higher in male
16
17 subjects (**Table 3**). As for the function of insulin secretion, insulinogenic index and
18
19 HOMA- β were significantly lower in men than in women. Insulin_{AUC} also showed a
20
21 tendency to be lower in male subjects. Reactive hypoglycemia during OGTT tended to
22
23 be frequent in men. The differences in the mean values of HbA1c and HOMA-IR were
24
25 not statistically significant. There were no significant gender differences in gestational
26
27 age ($p = 0.145$), birth weight ($p = 0.168$), age at study assessment ($p = 0.845$), BMI
28
29 ($p = 0.879$), the proportion of SGA ($p = 0.756$), and that of family history of diabetes
30
31 within the second degree ($p = 0.516$). The variables for glucose metabolism in men and
32
33 women are summarized in **Table 3**.
34
35
36
37
38
39
40
41
42
43
44
45

46 We evaluated the associations between gender and the variables of glucose metabolism
47
48 by multiple linear regression analysis. Adjustments were made for family history of
49
50 diabetes within the second degree, BMI, gestational age, birth weight, and SGA/AGA.
51
52 In this analysis, male gender had inverse associations with HOMA- β (β : -0.336; 95%
53
54
55
56
57
58
59
60

1
2
3
4
5
6 CI: -0.509 to -0.163; $p < 0.001$) and insulinogenic index (β : -0.195; 95% CI: -0.344 to
7
8
9 -0.047; $p=0.01$). Glucose_{AUC} during OGTT tended to be positively associated with male
10
11
12 gender (β : 0.056; 95% CI: -0.0047 to 0.116; $p=0.071$).

13
14
15 In male subjects, after an adjustment for family history of diabetes, BMI, gestational
16
17
18 age, and birth weight, the logistic regression analysis showed that SGA was a
19
20
21 statistically significant independent factor associated with hyperglycemia (Odds ratio:
22
23
24 33.3; 95% CI: 1.67-662.6; $p=0.022$).

25 26 27 28 29 **DISCUSSION**

30
31
32 To the best of our knowledge, this is the first study assessing the glucose regulation in
33
34
35 young adults with VLBW in an Asian population. Our study has indicated that 19% of
36
37
38 young adults with VLBW already had hyperglycemia: type 2 diabetes; IGT; IFG; and
39
40
41 non-diabetes/IGT/IFG with high 1-hour plasma glucose level. A report from the
42
43
44 Japanese Ministry of Health, Welfare, and Labour in 2007 showed that of 204 general
45
46
47 young adults (aged 20-29 years), 2 individuals (0.98%) had high levels of HbA1c (more
48
49
50 than 6.0%; NGSP equivalent values),¹⁸ while 3.6% of young adults with VLBW had the
51
52
53 HbA1c values more than 6.0% in the present study. In a previous study, Hovi et al.
54
55
56 reported that VLBW infants in young adulthood had higher indexes of glucose
57
58
59
60

1
2
3
4
5
6 intolerance compared with term infants.⁹ A recent epidemiological study has also shown
7
8
9 that preterm birth is associated with an increased risk of diabetes in young adults.⁸ On
10
11
12 the other hand, a study in the Netherlands showed that preterm birth was not associated
13
14
15 with reduced insulin sensitivity in young adulthood.¹⁹ The findings of that study may be
16
17
18 biased by the way of recruiting the control subjects born at term. Our findings would be
19
20
21 in line with the standpoint of high prevalence of hyperglycemia in premature infants in
22
23
24 young adulthood, although absence of control subjects presents a limitation of
25
26
27 demonstrating the impact of VLBW itself on glucose regulation.

28
29 We have also found that male subjects had higher glucose levels during OGTT than
30
31
32 females. Previous studies in the general population showed that women had higher
33
34
35 postload glucose levels than men, which were explained by differences in body size.^{20 21}
36
37
38 During standard 75-g OGTT, men and women take the same amount of glucose, which
39
40
41 is thought to be high dosage for women relative to their body size. In our study,
42
43
44 however, men had significantly higher levels of both fasting and postload glucose
45
46
47 concentrations during OGTT. Moreover, male gender was associated with lower beta
48
49
50 cell function and the risk of glucose intolerance. These findings might indicate that men
51
52
53 with VLBW are more predisposed to diabetes than women; indeed, recent studies have
54
55
56 shown that male premature infants are more vulnerable than females.²²⁻²⁷ In particular,
57
58
59
60

1
2
3
4
5
6 the male sex is associated with various adverse outcomes including death,^{25 27}
7
8
9 respiratory dysfunction,²² intraventricular hemorrhage,²⁴ autism spectrum,²³ and
10
11 neurodevelopmental impairment.²⁶ Interestingly, in the present study, the mean value of
12
13 height (155cm) in women with VLBW is close to the average value of the Japanese
14
15 female population (158cm), whereas men with VLBW (164cm) were found to be
16
17 shorter compared to the Japanese male population (171cm) (average height data of
18
19 Japanese population were drawn from the report by the Ministry of Education, Culture,
20
21 Sports, Science, and Technology in Japan).²⁸ In a previous study, young adults who had
22
23 been born SGA were shorter and had higher glucose levels than those with a normal
24
25 birth weight.²⁹ Reduced final height might be long term consequences of intrauterine
26
27 retardation, which would also influence glucose regulation. Further investigation is
28
29 needed to clarify whether the influence of VLBW on physical growth is more
30
31 remarkable in male than female infants, and elucidate the relationship between physical
32
33 growth and glucose regulation.
34
35
36
37
38
39
40
41
42
43
44
45

46 Previous studies have shown that SGA itself is associated with glucose intolerance.³⁰
47
48 In our study, SGA was not significantly associated with hyperglycemia in total subjects,
49
50 but was associated in male subjects. The influence of SGA on glucose regulation in
51
52 young adults with VLBW might be stronger in male than females. It is possible that this
53
54
55
56
57
58
59
60

1
2
3
4
5
6 gender difference in glucose regulation is owing to the gender difference in the strength
7
8
9 of SGA effect.
10

11 12 13 14 15 **Strength and weakness of the study** 16

17
18 The major strength of our study is a well-characterized cohort of subjects with VLBW,
19
20 who are quite rare in the general population (approximately 0.5% in this generation).³¹
21
22

23
24 Our study includes a relatively large number of young adults with VLBW, and the
25
26 individuals with profound complications were carefully excluded in the recruiting
27
28 process. In addition, as participants in the cohort were all Japanese, their racial
29
30 homogeneity made considerations of ethnic differences in glucose regulation
31
32 unnecessary. To date, the glucose regulation of Asian young adults with VLBW has
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

43
44 In the present study, we could not obtain information regarding the growth rate in
45
46 childhood of all participants. This is a major limitation of the study. The postnatal
47
48 growth pattern in infancy has been shown to be associated with later glucose
49
50 intolerance.³²⁻³⁵ The clinical records of participants were written 20 to 30 years ago, and
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6 age, smoking, gestational diabetes, and perinatal complications were not available in the
7
8
9 present study. These factors might have affected fetal malnutrition and subsequently led
10
11 to VLBW. In terms of subjects in the present study, our study has no control subjects,
12
13 presenting a limitation of demonstrating the impact of VLBW itself on glucose
14
15 regulation. Another concern of the study is selection bias. Of 301 VLBW subjects who
16
17 were thought to receive the invitation letters, 111 subjects participated in the study
18
19 (37%). The findings should be carefully interpreted taking into account the possibility
20
21 that the participants might not be representative of general young adults with VLBW.
22
23
24
25
26
27
28
29
30
31

32 **Future Perspective**

33
34
35 As neonatal intensive care is making steady progress, an increasing number of young
36
37 adults with VLBW worldwide will face a greater variety of health problems. Clinician
38
39 should be aware of the risk of hyperglycemia in young adults with VLBW, and follow
40
41 up them for a longer period of time. It may be worthwhile for them to check their
42
43 glucose metabolism with OGTT in their twenties or thirties, which would lead to early
44
45 intervention in their lifestyle and subsequently contribute to prevention of type 2
46
47 diabetes and cardiovascular disease.⁵⁻⁷ In the present study, we have found that male
48
49
50
51
52
53
54
55
56
57
58
59
60
gender was a significant independent risk factor of hyperglycemia in young adults with

1
2
3
4
5
6 VLBW. In addition to the gender difference, future studies are required to focus on the
7
8
9 factors affecting the glucose metabolism in VLBW infants.
10
11
12
13

14 **Acknowledgment:** The authors thank all the participants in this study; the pediatricians
15
16 who have treated the participants in their neonatal periods; the colleagues who made a
17
18 great contribution to the study as clinical research coordinators: Masahiro Asano,
19
20 Kikuko Tejima, Emiko Morita, Mari Suzuki, Kaoru Kikuchi, and Chieko Suzuki; the
21
22 colleagues who played vital roles by excellent technical assistance: Hiromi Kajima,
23
24 Takako Akiyama, and Masato Shouji; and Keisuke Ishii and Gregory O'Dowd for
25
26 encouraging advice on the present study.
27
28
29
30
31
32
33
34
35
36
37

38 **Contributors:** RS and HW drafted the paper. RS conceived the study. RS and KS
39
40 developed the idea. RS, HW, KS, SO, RG, MM, and HN were involved in study design.
41
42 RS and KS participated in data acquisition. RS, HW, HM, EI, MT, and MM were
43
44 engaged in data analysis. All the authors contributed to the interpretation of the findings.
45
46
47
48
49 All the authors were involved in the revision and approved the final version.
50
51

52 **Funding:** This study was partly supported by grants from the Japan Society for the
53
54 Promotion of Science (21390180) and from the Ministry of Health, Labour and Welfare
55
56
57
58
59
60

1
2
3
4
5
6 in Japan (H23-Cardiovascular disease and Diabetes-011).
7

8
9 **Competing Interest:** None.
10

11 **Ethical approval:** The study was approved by the ethical committee of Seirei
12
13 Hamamatsu General Hospital. All participants provided written informed consent to
14
15 participate in the study.
16
17
18

19
20 **Data sharing statement:** Data will not be publically accessible. However, interested
21
22 individuals may contact the authors.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Field DJ, Dorling JS, Manktelow BN, et al. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. *BMJ* 2008;336(7655):1221-3.
2. Barker DJ, Gluckman PD, Godfrey KM, et al. Fetal nutrition and cardiovascular disease in adult life. *Lancet* 1993;341(8850):938-41.
3. Kaijser M, Bonamy AK, Akre O, et al. Perinatal risk factors for diabetes in later life. *Diabetes* 2009;58(3):523-6.
4. Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. *JAMA* 2008;300(24):2886-97.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346(6):393-403.
6. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. *Diabetologia* 1991;34(12):891-8.
7. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344(18):1343-50.
8. Crump C, Winkleby MA, Sundquist K, et al. Risk of diabetes among young adults born preterm in Sweden. *Diabetes Care* 2011;34(5):1109-13.
9. Hovi P, Andersson S, Eriksson JG, et al. Glucose regulation in young adults with very low birth weight. *N Engl J Med* 2007;356(20):2053-63.
10. The study group of the Health Ministry in Japan. Fetal growth curves of Japanese, 1994. pp 61.
11. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999.
12. Abdul-Ghani MA, Abdul-Ghani T, Ali N, et al. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. *Diabetes Care* 2008;31(8):1650-5.
13. Succurro E, Marini MA, Arturi F, et al. Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. *Atherosclerosis* 2009;207(1):245-9.
14. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. *Diabetes Care*

- 2005;28(12):2948-61.
15. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. *J Japan Diab Soc* 2010; 53 450-67.
 16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28(7):412-9.
 17. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009;53(6):982-92.
 18. The Ministry of Health, Labour, and Welfare. The National Health and Nutrition Survey in Japan, 2007. pp 187.
 19. Willemsen RH, Leunissen RW, Stijnen T, et al. Prematurity is not associated with reduced insulin sensitivity in adulthood. *J Clin Endocrinol Metab* 2009;94(5):1695-700.
 20. Faerch K, Borch-Johnsen K, Vaag A, et al. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. *Diabetologia* 2010;53(5):858-65.
 21. Sicree RA, Zimmet PZ, Dunstan DW, et al. Differences in height explain gender differences in the response to the oral glucose tolerance test- the AusDiab study. *Diabet Med* 2008;25(3):296-302.
 22. Henderson-Smart DJ, Hutchinson JL, Donoghue DA, et al. Prenatal predictors of chronic lung disease in very preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2006;91(1):F40-5.
 23. Johnson S, Hollis C, Kochhar P, et al. Autism spectrum disorders in extremely preterm children. *J Pediatr* 2010;156(4):525-31 e2.
 24. Mohamed MA, Aly H. Male gender is associated with intraventricular hemorrhage. *Pediatrics* 2010;125(2):e333-9.
 25. Morse SB, Wu SS, Ma C, et al. Racial and gender differences in the viability of extremely low birth weight infants: a population-based study. *Pediatrics* 2006;117(1):e106-12.
 26. Spinillo A, Montanari L, Gardella B, et al. Infant sex, obstetric risk factors, and 2-year neurodevelopmental outcome among preterm infants. *Dev Med Child Neurol* 2009;51(7):518-25.
 27. Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. *N Engl J Med* 2008;358(16):1672-81.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. The Ministry of Education, Culture, Sports, Science, and Technology in Japan. A report of school health statistics, 2004.
 29. Leger J, Levy-Marchal C, Bloch J, et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. *BMJ* 1997;315(7104):341-7.
 30. Saenger P, Czernichow P, Hughes I, et al. Small for gestational age: short stature and beyond. *Endocr Rev* 2007;28(2):219-51.
 31. The Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour, and Welfare. Vital Statistics in Japan, 2009. Vol.1. pp 124-127.
 32. Crowther NJ, Cameron N, Trusler J, et al. Influence of catch-up growth on glucose tolerance and beta-cell function in 7-year-old children: results from the birth to twenty study. *Pediatrics* 2008;121(6):e1715-22.
 33. Eriksson JG, Osmond C, Kajantie E, et al. Patterns of growth among children who later develop type 2 diabetes or its risk factors. *Diabetologia* 2006;49(12):2853-8.
 34. Finken MJ, Keijzer-Veen MG, Dekker FW, et al. Preterm birth and later insulin resistance: effects of birth weight and postnatal growth in a population based longitudinal study from birth into adult life. *Diabetologia* 2006;49(3):478-85.
 35. Leunissen RW, Kerkhof GF, Stijnen T, et al. Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood. *JAMA* 2009;301(21):2234-42.

Table 1. Clinical characteristics of young adults with very low birth weight (VLBW) at birth and at study assessment

	Total (n=111)	Men (n=42)		Women (n=69)	
		SGA* (n=14)	AGA (n=28)	SGA* (n=25)	AGA (n=44)
At birth					
Gestational Age (wk)	29.7 (3.1)	31.5 (3.7)	28.1 (1.9)	33.0 (2.6)	28.2 (1.9)
Weight (g)	1152 (235)	1050 (223)	1149 (235)	1190 (239)	1166 (236)
ELBW	33 (29.7)	6 (42.9)	10 (35.7)	7 (28.0)	10 (22.7)
Birth from multiple pregnancy	18 (16.2)	2 (21.4)	7 (25.0)	1 (4.0)	8 (18.1)
At study assessment					
Age (yr)	24.8 (3.0)	24.9 (2.9)	24.6 (3.6)	23.9 (2.9)	25.4 (2.7)
Family history of diabetes	22 (19.8)	2 (14.3)	5 (17.9)	7 (28.0)	8 (18.2)
Height (m)	1.58 (0.07)	1.60 (0.06)	1.66 (0.06)	1.54 (0.06)	1.55 (0.05)
Body Weight (kg)	52.3 (10.1)	53.1 (8.8)	55.8 (8.9)	47.5 (8.3)	52.4 (11.3)
BMI (kg/m ²)	20.9 (3.8)	20.8 (3.2)	20.3 (2.8)	20.1 (3.0)	21.7 (4.7)
Blood pressure (mmHg)					
Systolic	118 (16)	120 (18)	121 (17)	115 (12)	117 (16)
Diastolic	70 (11)	69 (15)	69 (11)	69 (11)	71 (11)
Cholesterol (mg/dl)					
Total	184.8 (31.3)	210.6 (52.0)	183.4 (25.2)	180.4 (27.2)	179.9 (25.1)
LDL	104.3 (28.4)	126.9 (48.6)	104.8 (24.8)	100.3 (21.5)	99.0 (22.6)
HDL	65.7 (13.3)	63.2 (14.0)	64.6 (14.1)	64.6 (15.1)	67.8 (11.6)
Triglycerides (mg/dl)	81.8 (72.2)	126.5 (139.9)	81.0 (84.5)	85.4 (51.0)	65.9 (23.5)
Renal function					
Creatinine (mg/dl)	0.66 (0.13)	0.76 (0.09)	0.80 (0.11)	0.59 (0.08)	0.58 (0.08)
eGFR (ml/min/1.73 m ²) [†]	104.6 (18.4)	105.5 (13.9)	101.8 (19.4)	104.3 (18.2)	106.3 (19.5)

SGA, small for gestational age; AGA, appropriate for gestational age; ELBW, extremely low birth weight (<1000g); BMI, body mass index; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Data are expressed as mean (SD) or number (%).

1
2
3
4
5 *Determined by a birth weight below the 10th percentile for gestational age according
6 to standards defined by a study group of the Health Ministry in Japan.
7

8 †Calculated according to the formula recommended by the Japanese Society of
9 Nephrology: $eGFR \text{ (ml/min/1.73m}^2\text{)} = 194 \times \text{Cre}^{-1.094} \times \text{Age}^{-0.287}$ ($\times 0.739$ if the subject
10 is a woman).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2. Correlated factors for hyperglycemia* in young adults with very low birth weight (VLBW) assessed by logistic regression analyses

Variable	Odds Ratio†	95% CI	P-value
Gender (Male)	3.34	1.08 - 10.3	0.036
Factors at birth			
Gestational age (wk)	0.77	0.53 - 1.12	0.165
Weight (0.1kg)	1.39	0.96 - 2.02	0.085
SGA	2.56	0.37 - 17.5	0.340
Factors at study assessment			
Family history of diabetes	1.92	0.49 - 7.57	0.353
BMI (kg/m ²)	1.29	1.11 - 1.49	0.001

SGA, small for gestational age; BMI, body mass index.

*A category of hyperglycemia includes Diabetes, IGT (impaired glucose tolerance), IFG (impaired fasting glycaemia), and Non-diabetes/IGT/IFG with elevated 1-hour glucose levels (> 8.6mmol/l).

†Each odds ratio is calculated from a model including gender, family history of diabetes, BMI, gestational age, birth weight, and SGA/AGA (appropriate for gestational age).

Table 3. Gender differences in glucose regulation in young adults with very low birth weight (VLBW)

	Men (n=42)	Women (n=69)	P-value
Hyperglycemia	11 (26.2)	10 (14.5)	0.127
Diabetes	0	1	
IGT	2	4	
IFG	1	0	
Non-diabetes/IGT/IFG with elevated 1-hour glucose levels*	8	5	
HbA1c (%)	5.39 (5.31 - 5.47)	5.39 (5.31 - 5.47)	0.635
HOMA- β	72.5 (59.0 - 86.0)	103 (87.2 - 119.6)	0.001
HOMA-IR	1.4 (1.14 - 1.69)	1.6 (1.29 - 1.90)	0.477
Variable during OGTT			
Insulinogenic Index	1.1 (0.64 - 1.60)	1.4 (1.18 - 1.71)	0.002
Glucose _{AUC} (mmol/l \times hr)	18.8 (17.9 - 19.7)	18.2 (17.3 - 19.0)	0.089
Insulin _{AUC} (μ U/ml \times hr)	135.3 (98.7 - 171.9)	145.1 (121.7 - 168.6)	0.052
Reactive hypoglycemia	17 (40)	17 (25)	0.079

IGT, impaired glucose tolerance; IFG, impaired fasting glycemia; HOMA- β , homeostasis model of assessment for beta cell; HOMA-IR, homeostasis model of assessment for insulin resistance.

Data are expressed as mean (95% CI) or number (%).

*Defined as 1-hour glucose levels > 8.6mmol/l.

Figure Legends

Figure 1. Flow of participants through the study.

(There is no figure legend in Figure 1.)

Figure 2. The gender differences of glucose and insulin levels during OGTT in young adults with very low birth weight (VLBW).

The top and bottom of the box indicate lower and upper quartiles; the line inside the box represents the median; the whiskers indicate the most extreme data points within 1.5 times of interquartile range from the box; dots indicate outliers. Male subjects had significantly higher levels of glucose and lower levels of insulin during OGTT than female subjects ($p < 0.001$ for glucose and $p = 0.005$ for insulin by repeated measure ANOVA).

The numerical data of Figure 2.

Male (n=42)

	0 (min)	30	60	90	120	180
Plasma glucose (mg/dl)	5.208 (0.3695)	8.579 (1.272)	7.167 (1.824)	6.262 (1.523)	5.749 (1.102)	4.360 (1.205)
Insulin (microU/ml)	6.057 (3.519)	64.95 (64.53)	53.70 (47.86)	53.27 (49.61)	49.84 (50.66)	20.94 (24.37)

Female (n=69)

	0 (min)	30	60	90	120	180
Plasma glucose (mg/dl)	4.930 (0.4266)	7.529 (1.460)	6.596 (1.946)	6.178 (1.541)	5.829 (1.487)	4.881 (1.121)
Insulin (microU/ml)	7.090 (5.107)	66.22 (42.62)	57.09 (51.97)	54.95 (44.39)	51.11 (39.85)	31.82 (28.03)

Data are expressed as mean (SD).

Figure 1. Flow of Participants through the study.






Figure 2. The gender differences of glucose and insulin levels during OGTT in young adults with very low birth weight (VLBW).



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	n/a
Bias	9	Describe any efforts to address potential sources of bias	18
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-12
		(b) Describe any methods used to examine subgroups and interactions	13
		(c) Explain how missing data were addressed	n/a
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	n/a
Outcome data	15*	Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-14
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
Discussion			
Key results	18	Summarise key results with reference to study objectives	14-15
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	17-18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



A cross-sectional study of glucose regulation in young adults with very low birth weight: impact of male gender on hyperglycemia

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000327.R2
Article Type:	Research
Date Submitted by the Author:	25-Dec-2011
Complete List of Authors:	<p>Sato, Ryosuke; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II; Seirei Hamamatsu General Hospital, Department of Endocrinology and Metabolism</p> <p>Watanabe, Hiroshi; Hamamatsu University School of Medicine, Department of Clinical Pharmacology and Therapeutics</p> <p>Shirai, Kenji; Seirei Hamamatsu General Hospital, Department of Neonatology</p> <p>Ohki, Shigeru; Seirei Hamamatsu General Hospital, Department of Neonatology</p> <p>Genma, Rieko; Seirei Hamamatsu General Hospital, Department of Endocrinology and Metabolism</p> <p>Morita, Hiroshi; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II</p> <p>Inoue, Eisuke; Kitasato University, Department of Clinical Medicine (Biostatics)</p> <p>Takeuchi, Masahiro; Kitasato University, Department of Clinical Medicine (Biostatics)</p> <p>Maekawa, Masato; Hamamatsu University School of Medicine, Department of Laboratory Medicine</p> <p>Nakamura, Hirotohi; Hamamatsu University School of Medicine, Department of Endocrinology and Metabolism, Division of Internal Medicine II</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Paediatrics, Cardiovascular medicine
Keywords:	Diabetes Mellitus, Very low birth weight (VLBW), Small for gestational age (SGA), Gender difference, Oral glucose tolerance test (OGTT), hyperglycemia

1
2
3
4
5
6 **A cross-sectional study of glucose regulation in young adults with very**
7
8 **low birth weight: impact of male gender on hyperglycemia**
9
10

11
12
13
14
15 Ryosuke Sato,^{1,2} Hiroshi Watanabe,³ Kenji Shirai,⁴ Shigeru Ohki,⁴ Rieko Genma,²

16
17
18 Hiroshi Morita,¹ Eisuke Inoue,⁵ Masahiro Takeuchi,⁵ Masato Maekawa,⁶ Hirotooshi

19
20 Nakamura¹
21
22
23
24
25

26 **Address and Affiliations (position)**
27

28
29 ¹Department of Endocrinology and Metabolism, Division of Internal Medicine II, Hamamatsu
30 University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

31 Ryosuke Sato: Physician

32 Hiroshi Morita: Physician

33 Hirotooshi Nakamura: Professor
34
35
36

37 ²Department of Endocrinology and Metabolism, Seirei Hamamatsu General Hospital, 2-12-12,
38 Sumiyoshi, Naka-ku, Hamamatsu, 430-8558, Japan.

39 Ryosuke Sato: Physician

40 Rieko Genma: Physician
41
42
43
44

45 ³Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of
46 Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

47 Hiroshi Watanabe: Professor
48
49

50 ⁴Department of Neonatology, Seirei Hamamatsu General Hospital, 2-12-12, Sumiyoshi, Naka-ku,
51 Hamamatsu, 430-8558, Japan.

52 Kenji Shirai: Neonatologist

53 Shigeru Ohki: Neonatologist
54
55
56
57
58
59
60

⁵Department of Clinical Medicine (Biostatistics), Kitasato University, 5-9-1, Shirokane, Minato-ku, Tokyo, 108-8641, Japan.

Eisuke Inoue: Statistician

Masahiro Takeuchi: Professor

⁶Department of Laboratory Medicine, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

Masato Maekawa: Professor

Correspondence: Ryosuke Sato, MD, Department of Endocrinology and Metabolism,

Division of Internal Medicine II, Hamamatsu University School of Medicine, 1-20-1,

Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan. Tel: +81-53-435-2385; Fax:

+81-53-435-2386; E-mail: ryos@hama-med.ac.jp

Word counts for the abstract: 298

Word counts for the manuscript: 2430

The number of Bibliography: 35

The number of figures: 2

The number of tables: 3

Keywords: diabetes mellitus, very low birth weight (VLBW), small for gestational age

(SGA), gender difference, oral glucose tolerance test (OGTT)

ABSTRACT

Objectives: To investigate glucose regulation in young adults with very low birth weight (VLBW; <1500g) in an Asian population.

Design: Cross-sectional, observational study.

Setting: A general hospital in Hamamatsu, Japan.

Participants: 111 young adults (42 men and 69 women; aged 19-30 years) born with VLBW between 1980 and 1990. Participants underwent standard 75-g oral glucose tolerance test (OGTT).

Primary and secondary outcome measures: The primary outcomes were glucose and insulin levels during OGTT, and risk factors for a category of hyperglycemia defined as follows: diabetes mellitus; impaired glucose tolerance (IGT); impaired fasting glycemia (IFG); and non-diabetes/IGT/IFG with elevated 1-hour glucose levels (>8.6 mmol/l). The secondary outcomes were the pancreatic beta cell function (insulinogenic index and homeostasis model of assessment for beta cell [HOMA- β]), and insulin resistance (homeostasis model of assessment for insulin resistance [HOMA-IR]).

Results: Of 111 young adults with VLBW, 21 subjects (19%) had hyperglycemia: 1 had type 2 diabetes; 6 had IGT; 1 had IFG; and 13 had non-diabetes/IGT/IFG with elevated 1-hour glucose levels. In logistic regression analysis, male gender was an independent

1
2
3
4
5
6 risk factor associated with hyperglycemia (OR: 3.34; 95%CI: 1.08-10.3; p=0.036). Male
7
8
9 subjects had significantly higher levels of glucose and lower levels of insulin during
10
11
12 OGTT than female subjects (p<0.001 for glucose and p=0.005 for insulin by repeated
13
14
15 measures ANOVA). Pancreatic beta cell function was lower in men (insulinogenic
16
17
18 index: p=0.002; HOMA- β : p=0.001), although no gender difference was found in
19
20
21 insulin resistance (HOMA-IR: p=0.477). In male subjects, logistic regression analysis
22
23
24 showed that small for gestational age (SGA) was an independent risk factor associated
25
26
27 with hyperglycemia (OR: 33.3; 95%CI: 1.67-662.6; p=0.022).

28
29 **Conclusions:** 19% of individuals with VLBW already had hyperglycemia in young
30
31
32 adulthood, and male gender was a significant independent risk factor of hyperglycemia.
33
34
35 In male young adults with VLBW, SGA was associated with hyperglycemia.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Neonatal intensive care has improved the survival rate for very low birth weight infants (VLBW; birth weight <1500g) in recent decades, and the first generation of VLBW infants have only recently reached young adulthood.
- Only a few studies have shown that VLBW (or preterm) is associated with glucose intolerance in Caucasian young adults, while glucose regulation in Asian young adults with VLBW is still uncertain.
- The present study investigated glucose regulation in young adults with VLBW in an Asian population, and determined the factors associated with hyperglycemia.

Key messages

- Of 111 young adults with VLBW, 19% of individuals already had hyperglycemia (type 2 diabetes, IGT, IFG, and non-diabetes/IGT/IFG with elevated 1-hour glucose levels).
- Male gender was a significant independent risk factor of hyperglycemia in young adults with VLBW.
- Small for gestational age (SGA) was associated with hyperglycemia particularly in

1
2
3
4
5
6 male young adults with VLBW.
7
8
9
10

11 **Strengths and limitations of this study**

- 12
- 13 ■ This is the first study assessing the glucose regulation in young adults with VLBW
 - 14
 - 15 in an Asian population.
 - 16
 - 17
 - 18
 - 19
 - 20 ■ This study does not provide information on postnatal growth patterns, which have
 - 21
 - 22 been shown to be associated with later hyperglycemia in previous studies.
 - 23
 - 24
 - 25
 - 26 ■ The study design with no control subjects makes it impossible to address the
 - 27
 - 28 delayed impact of VLBW itself on glucose regulation.
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60

INTRODUCTION

In recent decades, progression of neonatal intensive care has dramatically increased the survival rate of very low birth weight (VLBW; birth weight <1500g) infants worldwide.¹ A lot of them have grown up into young adult (now in their twenties or thirties). To date, epidemiological studies have shown an association between low birth weight and type 2 diabetes and cardiovascular disease in later life.²⁻⁴ Fetal malnutrition in the gestational period, which prevents appropriate fetal growth in utero, is thought to provoke thrifty phenotype in premature babies. This phenotype is assumed to predispose them to subsequent metabolic disorders. For this reason, to foresee the later risk of type 2 diabetes is very crucial for VLBW infants, which would lead to prevention of type 2 diabetes by early intervention in their lifestyle.⁵⁻⁷

The first generation of VLBW infants have only recently reached young adulthood. A few studies have shown that VLBW (or preterm) is associated with glucose intolerance in young adulthood in Caucasian populations,^{8,9} while the glucose regulation in Asian young adults with VLBW remains uncertain. To clarify the characteristics of glucose metabolism in young adults with VLBW in an Asian population, we investigated glucose regulation in 111 young adults with VLBW by performing detailed oral glucose tolerance test (OGTT), which is useful for evaluation of early signs of glucose

1
2
3
4
5
6 intolerance.

7 8 9 10 11 12 **METHODS**

13 14 15 **Study Participants**

16
17 The birth record database of Seirei Hamamatsu General Hospital (Hamamatsu, Japan)
18 showed that 628 subjects were born with VLBW between 1980 and 1990, and were
19 treated at a neonatal intensive care unit (**Figure 1**). VLBW infants were defined
20 according to the World Health Organization (WHO) criteria: babies whose birth weight
21 was less than 1500g. Out of the 628 subjects, 229 were excluded because of death
22 (n=132) or severe neurodevelopmental impairment (n=97). To the remaining 399
23 subjects, we sent letters which provided information regarding the study and requested
24 their participation. Among the 399 letters, 98 were returned marked as address unknown
25 (i.e. the remaining 301 letters were thought to reach their destinations). Consequently,
26 111 subjects (aged 19-30 years) participated in the present study. All participants were
27 Japanese. Small for gestational age (SGA) status was determined according to standards
28 by a study group of the Health Ministry in Japan: a birth weight below the 10th
29 percentile for gestational age.¹⁰ The basal characteristics of participants at birth are
30 summarized in **Table 1**.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Measurements

All participants underwent a standard 75-g OGTT after a ten-hour overnight fast.

Plasma glucose and serum insulin concentrations were examined at 0, 30, 60, 90, 120, and 180 minutes during OGTT. Fasting glucose levels and 2-hour glucose levels were used for diagnosing diabetes mellitus, impaired glucose tolerance (IGT), and impaired fasting glycaemia (IFG) according to the WHO criteria.¹¹ Since it has been shown that 1-hour plasma glucose concentration is associated with future risk of type 2 diabetes and atherosclerosis, 1-hour plasma glucose above 8.6 mmol/l (155 mg/dl) was included as a category of hyperglycemia.^{12 13} Reactive hypoglycemia during OGTT was defined as the level of plasma glucose less than 3.8 mmol/l which causes the response of counter-regulatory hormone release.¹⁴

We measured plasma glucose and serum insulin levels during OGTT with an autoanalyzer JCA-BM2250 (JEOL, Tokyo, Japan). Plasma glucose was measured by means of hexokinase method. The concentration of serum insulin was measured with chemiluminescent enzyme immunoassay (CLIA). Fasting blood samples were also drawn for other measurements; total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride, and creatinine.

1
2
3
4
5
6 Glycated haemoglobin A1c (HbA1c) was measured with high-performance liquid
7
8
9 chromatography (HPLC) method using an automated glycohaemoglobin analyzer
10
11
12 HLC-723G8 (Tosoh Bioscience, Tokyo, Japan). The values for HbA1c were converted
13
14
15 from Japanese Diabetes Society (JDS) values into National Glycohaemoglobin
16
17
18 Standardization Program (NGSP) equivalent values. NGSP equivalent values were
19
20
21 calculated with the formula: $\text{HbA1c (\%)} = \text{JDS value (\%)} + 0.4$.¹⁵
22
23
24
25

26 **Calculations and Statistical analysis**

27
28
29 Pancreatic beta cell function was evaluated by both insulinogenic index and
30
31
32 homeostasis model of assessment for beta cell (HOMA- β).¹⁶ Insulinogenic index, the
33
34
35 index of early-phase insulin secretion, was calculated as the ratio of the increment in
36
37
38 insulin concentration to the increment in glucose concentration ($[\text{30-min insulin}$
39
40
41 $(\mu\text{U/ml}) - \text{fasting insulin}] / [\text{30-min glucose (mmol/l)} - \text{fasting glucose}]$). HOMA- β was
42
43
44 calculated as follows: $20 \times \text{fasting insulin } (\mu\text{U/ml}) / [\text{fasting glucose (mmol/l)} - 3.5]$.
45
46
47 Insulin resistance was estimated by homeostasis model of assessment for insulin
48
49
50 resistance (HOMA-IR): $\text{fasting insulin } (\mu\text{U/ml}) \times \text{fasting glucose (mmol/l)} / 22.5$.¹⁶ The
51
52
53 total amounts of glucose and insulin levels during OGTT were assessed by calculating
54
55
56 areas under the curve (AUC) with trapezoid rules. The estimated glomerular filtration
57
58
59
60

1
2
3
4
5
6 rate (eGFR) was calculated according to the following formula, as recommended by the

7
8
9 Japanese Society of Nephrology: $eGFR \text{ (ml/min/1.73m}^2\text{)} = 194 \times [\text{Cre (mg/dl)}]^{-1.094} \times$
10
11
12 $[\text{Age (years)}]^{-0.287}$ ($\times 0.739$ if the subject is a woman).¹⁷
13

14
15 Quantitative variables were expressed as mean and standard deviation (SD) or 95%
16
17 confidence interval (CI); categorical variables were presented as number and percentage.
18
19 Differences between groups were compared using the Student's t-test, the
20
21 Mann–Whitney U test, the Pearson's χ^2 test, or the repeated measures analysis of
22
23 variance (ANOVA) as appropriate. The data on insulin levels during OGTT were
24
25 logarithmically transformed before the repeated measures ANOVA. Logistic regression
26
27 analysis which included gender, family history of diabetes within the second degree,
28
29 BMI, gestational age, birth weight, and SGA/AGA (appropriate for gestational age) was
30
31 performed to estimate odds ratios for the category of hyperglycemia. For the further
32
33 investigation into glucose regulation, multiple linear regression analysis was conducted.
34
35 Gender, family history of diabetes, BMI, gestational age, birth weight, and SGA/AGA
36
37 were included in the model. The data on HOMA- β , HOMA-IR, Insulinogenic Index,
38
39 and Glucose_{AUC} were logarithmically transformed before analysis to meet the
40
41 assumptions of normality. A p-value of less than 0.05 was defined as statistically
42
43 significant. All analyses were conducted using SAS software version 9.2 (SAS Institute,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Cary, North Carolina, USA) and the statistical software R version 2.12.2
7
8
9 (http://www.r-project.org).
10

11 12 13 14 15 **RESULTS**

16
17 The basic characteristics of participants at study assessment are shown in **Table 1**. Of
18
19 111 young adults with VLBW, 21 subjects (19%) had hyperglycemia: one had type 2
20
21 diabetes; six had impaired glucose tolerance (IGT); one had impaired fasting glycaemia
22
23 (IFG); 13 non-diabetes/IGT/IFG subjects had elevated 1-hour glucose levels (>8.6
24
25 mmol/l). Hyperglycemia was more frequent in men than women (26.2 % for men vs
26
27 14.5 % for women). In the logistic regression analysis adjusted for family history of
28
29 diabetes within the second degree, BMI, gestational age, birth weight and SGA/AGA,
30
31 male gender was a statistically significant independent factor associated with
32
33 hyperglycemia (Odds ratio: 3.34; 95% CI: 1.08-10.3; p= 0.036). BMI at study
34
35 assessment was also associated with hyperglycemia (**Table 2**).
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Gender difference**

50
51 As male gender was a significant independent risk factor of hyperglycemia, we
52
53 evaluated the differences in glucose regulation between men and women in the sample
54
55
56
57
58
59
60

1
2
3
4
5
6 group. **Figure 2** shows the glucose and insulin response during OGTT in men and
7
8
9 women. Male subjects had significantly higher levels of glucose during OGTT than
10
11
12 female subjects ($p < 0.001$ by repeated measures ANOVA). In terms of insulin levels,
13
14
15 male subjects had lower levels of insulin during OGTT than female subjects ($p = 0.005$
16
17
18 by repeated measures ANOVA). Glucose_{AUC} during OGTT tended to be higher in male
19
20
21 subjects (**Table 3**). As for the function of insulin secretion, insulinogenic index and
22
23
24 HOMA- β were significantly lower in men than in women. Insulin_{AUC} also showed a
25
26
27 tendency to be lower in male subjects. Reactive hypoglycemia during OGTT tended to
28
29
30 be frequent in men. The differences in the mean values of HbA1c and HOMA-IR were
31
32
33 not statistically significant. There were no significant gender differences in gestational
34
35
36 age ($p = 0.145$), birth weight ($p = 0.168$), age at study assessment ($p = 0.845$), BMI
37
38
39 ($p = 0.879$), the proportion of SGA ($p = 0.756$), and that of family history of diabetes
40
41
42 within the second degree ($p = 0.516$). The variables for glucose metabolism in men and
43
44
45 women are summarized in **Table 3**.

46
47 We evaluated the associations between gender and the variables of glucose metabolism
48
49
50 by multiple linear regression analysis. Adjustments were made for family history of
51
52
53 diabetes within the second degree, BMI, gestational age, birth weight, and SGA/AGA.
54
55
56 In this analysis, male gender had inverse associations with HOMA- β (β : -0.336; 95%

1
2
3
4
5
6 CI: -0.509 to -0.163; $p < 0.001$) and insulinogenic index (β : -0.195; 95% CI: -0.344 to
7
8
9 -0.047; $p=0.01$). Glucose_{AUC} during OGTT tended to be positively associated with male
10
11
12 gender (β : 0.056; 95% CI: -0.0047 to 0.116; $p=0.071$).

13
14
15 In male subjects, after an adjustment for family history of diabetes, BMI, gestational
16
17
18 age, and birth weight, the logistic regression analysis showed that SGA was a
19
20
21 statistically significant independent factor associated with hyperglycemia (Odds ratio:
22
23
24 33.3; 95% CI: 1.67-662.6; $p=0.022$).

25 26 27 28 29 **DISCUSSION**

30
31
32 To the best of our knowledge, this is the first study assessing the glucose regulation in
33
34
35 young adults with VLBW in an Asian population. Our study has indicated that 19% of
36
37
38 young adults with VLBW already had hyperglycemia: type 2 diabetes; IGT; IFG; and
39
40
41 non-diabetes/IGT/IFG with high 1-hour plasma glucose level. A report from the
42
43
44 Japanese Ministry of Health, Welfare, and Labour in 2007 showed that of 204 general
45
46
47 young adults (aged 20-29 years), 2 individuals (0.98%) had high levels of HbA1c (more
48
49
50 than 6.0%; NGSP equivalent values),¹⁸ while 3.6% of young adults with VLBW had the
51
52
53 HbA1c values more than 6.0% in the present study. In a previous study, Hovi et al.
54
55
56 reported that VLBW infants in young adulthood had higher indexes of glucose
57
58
59
60

1
2
3
4
5
6 intolerance compared with term infants.⁹ A recent epidemiological study has also shown
7
8 that preterm birth is associated with an increased risk of diabetes in young adults.⁸ On
9
10 the other hand, a study in the Netherlands showed that preterm birth was not associated
11
12 with reduced insulin sensitivity in young adulthood.¹⁹ The findings of that study may be
13
14 biased by the way of recruiting the control subjects born at term. Our findings would be
15
16 in line with the standpoint of high prevalence of hyperglycemia in premature infants in
17
18 young adulthood, although absence of control subjects presents a limitation of
19
20 demonstrating the impact of VLBW itself on glucose regulation.
21
22
23
24
25
26
27

28
29 We have also found that male subjects had higher glucose levels during OGTT than
30
31 females. Previous studies in the general population showed that women had higher
32
33 postload glucose levels than men, which were explained by differences in body size.^{20 21}
34
35 During standard 75-g OGTT, men and women take the same amount of glucose, which
36
37 is thought to be high dosage for women relative to their body size. In our study,
38
39 however, men had significantly higher levels of both fasting and postload glucose
40
41 concentrations during OGTT. Moreover, male gender was associated with lower beta
42
43 cell function and the risk of glucose intolerance. These findings might indicate that men
44
45 with VLBW are more predisposed to diabetes than women; indeed, recent studies have
46
47 shown that male premature infants are more vulnerable than females.²²⁻²⁷ In particular,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 the male sex is associated with various adverse outcomes including death,^{25 27}
7
8
9 respiratory dysfunction,²² intraventricular hemorrhage,²⁴ autism spectrum,²³ and
10
11 neurodevelopmental impairment.²⁶ Interestingly, in the present study, the mean value of
12
13 height (155cm) in women with VLBW is close to the average value of the Japanese
14
15 female population (158cm), whereas men with VLBW (164cm) were found to be
16
17 shorter compared to the Japanese male population (171cm) (average height data of
18
19 Japanese population were drawn from the report by the Ministry of Education, Culture,
20
21 Sports, Science, and Technology in Japan).²⁸ In a previous study, young adults who had
22
23 been born SGA were shorter and had higher glucose levels than those with a normal
24
25 birth weight.²⁹ Reduced final height might be long term consequences of intrauterine
26
27 retardation, which would also influence glucose regulation. Further investigation is
28
29 needed to clarify whether the influence of VLBW on physical growth is more
30
31 remarkable in male than female infants, and elucidate the relationship between physical
32
33 growth and glucose regulation.
34
35
36
37
38
39
40
41
42
43
44
45

46 Previous studies have shown that SGA itself is associated with glucose intolerance.³⁰
47
48 In our study, SGA was not significantly associated with hyperglycemia in total subjects,
49
50 but was associated in male subjects. The influence of SGA on glucose regulation in
51
52 young adults with VLBW might be stronger in male than females. It is possible that this
53
54
55
56
57
58
59
60

1
2
3
4
5
6 gender difference in glucose regulation is owing to the gender difference in the strength
7
8
9 of SGA effect.
10

11 12 13 14 **Strength and weakness of the study** 15

16
17 The major strength of our study is a well-characterized cohort of subjects with VLBW,
18
19 who are quite rare in the general population (approximately 0.5% in this generation).³¹
20
21

22
23 Our study includes a relatively large number of young adults with VLBW, and the
24
25 individuals with profound complications were carefully excluded in the recruiting
26
27 process. In addition, as participants in the cohort were all Japanese, their racial
28
29 homogeneity made considerations of ethnic differences in glucose regulation
30
31 unnecessary. To date, the glucose regulation of Asian young adults with VLBW has
32
33 been uncertain. Our findings would be useful to clinicians and researchers, and
34
35 stimulate future large-scale prospective cohort studies in Asian populations.
36
37
38
39
40
41
42

43
44 In the present study, we could not obtain information regarding the growth rate in
45
46 childhood of all participants. This is a major limitation of the study. The postnatal
47
48 growth pattern in infancy has been shown to be associated with later glucose
49
50 intolerance.³²⁻³⁵ The clinical records of participants were written 20 to 30 years ago, and
51
52
53
54
55 some of them were no longer preserved. Additionally, maternal factors such as advanced
56
57
58
59
60

1
2
3
4
5
6 age, smoking, gestational diabetes, and perinatal complications were not available in the
7
8
9 present study. These factors might have affected fetal malnutrition and subsequently led
10
11 to VLBW. In terms of subjects in the present study, our study has no control subjects,
12
13 presenting a limitation of demonstrating the impact of VLBW itself on glucose
14
15 regulation. Another concern of the study is selection bias. Of 301 VLBW subjects who
16
17 were thought to receive the invitation letters, 111 subjects (37%) participated in the
18
19 study ~~(37%)~~. The findings should be carefully interpreted taking into account the
20
21 possibility that the participants might not be representative of general young adults with
22
23 VLBW.
24
25
26
27
28
29
30
31
32
33
34

35 **Future Perspective**

36
37
38 As neonatal intensive care is making steady progress, an increasing number of young
39
40 adults with VLBW worldwide will face a greater variety of health problems. Clinician
41
42 should be aware of the risk of hyperglycemia in young adults with VLBW, and follow
43
44 up them for a longer period of time. It may be worthwhile for them to check their
45
46 glucose metabolism with OGTT in their twenties or thirties, which would lead to early
47
48 intervention in their lifestyle and subsequently contribute to prevention of type 2
49
50 diabetes and cardiovascular disease.⁵⁻⁷ In the present study, we have found that male
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 gender was a significant independent risk factor of hyperglycemia in young adults with
7
8
9 VLBW. In addition to the gender difference, future studies are required to focus on the
10
11
12 factors affecting the glucose metabolism in VLBW infants.
13

14
15
16
17 **Acknowledgment:** The authors thank all the participants in this study; the pediatricians
18
19 who have treated the participants in their neonatal periods; the colleagues who made a
20
21 great contribution to the study as clinical research coordinators: Masahiro Asano,
22
23 Kikuko Tejima, Emiko Morita, Mari Suzuki, Kaoru Kikuchi, and Chieko Suzuki; the
24
25 colleagues who played vital roles by excellent technical assistance: Hiromi Kajima,
26
27 Takako Akiyama, and Masato Shouji; and Keisuke Ishii and Gregory O'Dowd for
28
29 encouraging advice on the present study.
30
31
32
33
34
35
36
37
38
39

40
41 **Contributors:** RS and HW drafted the paper. RS conceived the study. RS and KS
42
43 developed the idea. RS, HW, KS, SO, RG, MM, and HN were involved in study design.
44
45 RS and KS participated in data acquisition. RS, HW, HM, EI, MT, and MM were
46
47 engaged in data analysis. All the authors contributed to the interpretation of the findings.
48
49
50 All the authors were involved in the revision and approved the final version.
51
52
53
54

55
56 **Funding:** This study was partly supported by grants from the Japan Society for the
57
58
59
60

1
2
3
4
5
6 Promotion of Science (21390180) and from the Ministry of Health, Labour and Welfare
7
8
9 in Japan (H23-Cardiovascular disease and Diabetes-011).

10
11
12 **Competing Interest:** None.

13
14
15 **Ethical approval:** The study was approved by the ethical committee of Seirei
16
17 Hamamatsu General Hospital. All participants provided written informed consent to
18
19 participate in the study.
20
21

22
23
24 **Data sharing statement:** Data will not be publically accessible. However, interested
25
26 individuals may contact the authors.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Field DJ, Dorling JS, Manktelow BN, et al. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. *BMJ* 2008;336(7655):1221-3.
2. Barker DJ, Gluckman PD, Godfrey KM, et al. Fetal nutrition and cardiovascular disease in adult life. *Lancet* 1993;341(8850):938-41.
3. Kaijser M, Bonamy AK, Akre O, et al. Perinatal risk factors for diabetes in later life. *Diabetes* 2009;58(3):523-6.
4. Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. *JAMA* 2008;300(24):2886-97.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346(6):393-403.
6. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. *Diabetologia* 1991;34(12):891-8.
7. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344(18):1343-50.
8. Crump C, Winkleby MA, Sundquist K, et al. Risk of diabetes among young adults born preterm in Sweden. *Diabetes Care* 2011;34(5):1109-13.
9. Hovi P, Andersson S, Eriksson JG, et al. Glucose regulation in young adults with very low birth weight. *N Engl J Med* 2007;356(20):2053-63.
10. The study group of the Health Ministry in Japan. Fetal growth curves of Japanese, 1994. pp 61.
11. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999.
12. Abdul-Ghani MA, Abdul-Ghani T, Ali N, et al. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. *Diabetes Care* 2008;31(8):1650-5.
13. Succurro E, Marini MA, Arturi F, et al. Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. *Atherosclerosis* 2009;207(1):245-9.
14. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. *Diabetes Care*

- 2005;28(12):2948-61.
15. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. *J Japan Diab Soc* 2010; 53 450-67.
 16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28(7):412-9.
 17. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009;53(6):982-92.
 18. The Ministry of Health, Labour, and Welfare. The National Health and Nutrition Survey in Japan, 2007. pp 187.
 19. Willemsen RH, Leunissen RW, Stijnen T, et al. Prematurity is not associated with reduced insulin sensitivity in adulthood. *J Clin Endocrinol Metab* 2009;94(5):1695-700.
 20. Faerch K, Borch-Johnsen K, Vaag A, et al. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. *Diabetologia* 2010;53(5):858-65.
 21. Sicree RA, Zimmet PZ, Dunstan DW, et al. Differences in height explain gender differences in the response to the oral glucose tolerance test- the AusDiab study. *Diabet Med* 2008;25(3):296-302.
 22. Henderson-Smart DJ, Hutchinson JL, Donoghue DA, et al. Prenatal predictors of chronic lung disease in very preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2006;91(1):F40-5.
 23. Johnson S, Hollis C, Kochhar P, et al. Autism spectrum disorders in extremely preterm children. *J Pediatr* 2010;156(4):525-31 e2.
 24. Mohamed MA, Aly H. Male gender is associated with intraventricular hemorrhage. *Pediatrics* 2010;125(2):e333-9.
 25. Morse SB, Wu SS, Ma C, et al. Racial and gender differences in the viability of extremely low birth weight infants: a population-based study. *Pediatrics* 2006;117(1):e106-12.
 26. Spinillo A, Montanari L, Gardella B, et al. Infant sex, obstetric risk factors, and 2-year neurodevelopmental outcome among preterm infants. *Dev Med Child Neurol* 2009;51(7):518-25.
 27. Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. *N Engl J Med* 2008;358(16):1672-81.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. The Ministry of Education, Culture, Sports, Science, and Technology in Japan. A report of school health statistics, 2004.
 29. Leger J, Levy-Marchal C, Bloch J, et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. *BMJ* 1997;315(7104):341-7.
 30. Saenger P, Czernichow P, Hughes I, et al. Small for gestational age: short stature and beyond. *Endocr Rev* 2007;28(2):219-51.
 31. The Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour, and Welfare. Vital Statistics in Japan, 2009. Vol.1. pp 124-127.
 32. Crowther NJ, Cameron N, Trusler J, et al. Influence of catch-up growth on glucose tolerance and beta-cell function in 7-year-old children: results from the birth to twenty study. *Pediatrics* 2008;121(6):e1715-22.
 33. Eriksson JG, Osmond C, Kajantie E, et al. Patterns of growth among children who later develop type 2 diabetes or its risk factors. *Diabetologia* 2006;49(12):2853-8.
 34. Finken MJ, Keijzer-Veen MG, Dekker FW, et al. Preterm birth and later insulin resistance: effects of birth weight and postnatal growth in a population based longitudinal study from birth into adult life. *Diabetologia* 2006;49(3):478-85.
 35. Leunissen RW, Kerkhof GF, Stijnen T, et al. Timing and tempo of first-year rapid growth in relation to cardiovascular and metabolic risk profile in early adulthood. *JAMA* 2009;301(21):2234-42.

Table 1. Clinical characteristics of young adults with very low birth weight (VLBW) at birth and at study assessment

	Total (n=111)	Men (n=42)		Women (n=69)	
		SGA* (n=14)	AGA (n=28)	SGA* (n=25)	AGA (n=44)
At birth					
Gestational Age (wk)	29.7 (3.1)	31.5 (3.7)	28.1 (1.9)	33.0 (2.6)	28.2 (1.9)
Weight (g)	1152 (235)	1050 (223)	1149 (235)	1190 (239)	1166 (236)
ELBW	33 (29.7)	6 (42.9)	10 (35.7)	7 (28.0)	10 (22.7)
Birth from multiple pregnancy	18 (16.2)	2 (21.4)	7 (25.0)	1 (4.0)	8 (18.1)
At study assessment					
Age (yr)	24.8 (3.0)	24.9 (2.9)	24.6 (3.6)	23.9 (2.9)	25.4 (2.7)
Family history of diabetes	22 (19.8)	2 (14.3)	5 (17.9)	7 (28.0)	8 (18.2)
Height (m)	1.58 (0.07)	1.60 (0.06)	1.66 (0.06)	1.54 (0.06)	1.55 (0.05)
Body Weight (kg)	52.3 (10.1)	53.1 (8.8)	55.8 (8.9)	47.5 (8.3)	52.4 (11.3)
BMI (kg/m ²)	20.9 (3.8)	20.8 (3.2)	20.3 (2.8)	20.1 (3.0)	21.7 (4.7)
Blood pressure (mmHg)					
Systolic	118 (16)	120 (18)	121 (17)	115 (12)	117 (16)
Diastolic	70 (11)	69 (15)	69 (11)	69 (11)	71 (11)
Cholesterol (mg/dl)					
Total	184.8 (31.3)	210.6 (52.0)	183.4 (25.2)	180.4 (27.2)	179.9 (25.1)
LDL	104.3 (28.4)	126.9 (48.6)	104.8 (24.8)	100.3 (21.5)	99.0 (22.6)
HDL	65.7 (13.3)	63.2 (14.0)	64.6 (14.1)	64.6 (15.1)	67.8 (11.6)
Triglycerides (mg/dl)	81.8 (72.2)	126.5 (139.9)	81.0 (84.5)	85.4 (51.0)	65.9 (23.5)
Renal function					
Creatinine (mg/dl)	0.66 (0.13)	0.76 (0.09)	0.80 (0.11)	0.59 (0.08)	0.58 (0.08)
eGFR (ml/min/1.73 m ²) [†]	104.6 (18.4)	105.5 (13.9)	101.8 (19.4)	104.3 (18.2)	106.3 (19.5)

SGA, small for gestational age; AGA, appropriate for gestational age; ELBW, extremely low birth weight (<1000g); BMI, body mass index; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Data are expressed as mean (SD) or number (%).

1
2
3
4
5 *Determined by a birth weight below the 10th percentile for gestational age according
6 to standards defined by a study group of the Health Ministry in Japan.
7

8 †Calculated according to the formula recommended by the Japanese Society of
9 Nephrology: $eGFR \text{ (ml/min/1.73m}^2\text{)} = 194 \times [\text{Cre (mg/dl)}]^{-1.094} \times [\text{Age (years)}]^{-0.287}$ (\times
10 0.739 if the subject is a woman).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2. Correlated factors for hyperglycemia* in young adults with very low birth weight (VLBW) assessed by logistic regression analyses

Variable	Odds Ratio†	95% CI	P-value
Gender (Male)	3.34	1.08 - 10.3	0.036
Factors at birth			
Gestational age (wk)	0.77	0.53 - 1.12	0.165
Weight (0.1kg)	1.39	0.96 - 2.02	0.085
SGA	2.56	0.37 - 17.5	0.340
Factors at study assessment			
Family history of diabetes	1.92	0.49 - 7.57	0.353
BMI (kg/m ²)	1.29	1.11 - 1.49	0.001

SGA, small for gestational age; BMI, body mass index.

*A category of hyperglycemia includes Diabetes, IGT (impaired glucose tolerance), IFG (impaired fasting glycaemia), and Non-diabetes/IGT/IFG with elevated 1-hour glucose levels (> 8.6mmol/l).

†Each odds ratio is calculated from a model including gender, family history of diabetes, BMI, gestational age, birth weight, and SGA/AGA (appropriate for gestational age).

Table 3. Gender differences in glucose regulation in young adults with very low birth weight (VLBW)

	Men (n=42)	Women (n=69)	P-value
Hyperglycemia	11 (26.2)	10 (14.5)	0.127
Diabetes	0	1	
IGT	2	4	
IFG	1	0	
Non-diabetes/IGT/IFG with elevated 1-hour glucose levels*	8	5	
HbA1c (%)	5.39 (5.31 - 5.47)	5.39 (5.31 - 5.47)	0.635
HOMA- β	72.5 (59.0 - 86.0)	103 (87.2 - 119.6)	0.001
HOMA-IR	1.4 (1.14 - 1.69)	1.6 (1.29 - 1.90)	0.477
Variable during OGTT			
Insulinogenic Index	1.1 (0.64 - 1.60)	1.4 (1.18 - 1.71)	0.002
Glucose _{AUC} (mmol/l \times hr)	18.8 (17.9 - 19.7)	18.2 (17.3 - 19.0)	0.089
Insulin _{AUC} (μ U/ml \times hr)	135.3 (98.7 - 171.9)	145.1 (121.7 - 168.6)	0.052
Reactive hypoglycemia	17 (40)	17 (25)	0.079

IGT, impaired glucose tolerance; IFG, impaired fasting glycemia; HOMA- β , homeostasis model of assessment for beta cell; HOMA-IR, homeostasis model of assessment for insulin resistance.

Data are expressed as mean (95% CI) or number (%).

*Defined as 1-hour glucose levels > 8.6mmol/l.

Figure Legends

Figure 1. Flow of participants through the study.

(There is no figure legend in Figure 1.)

Figure 2. The gender differences of glucose and insulin levels during OGTT in young adults with very low birth weight (VLBW).

The top and bottom of the box indicate lower and upper quartiles; the line inside the box represents the median; the whiskers indicate the most extreme data points within 1.5 times of interquartile range from the box; dots indicate outliers. Male subjects had significantly higher levels of glucose and lower levels of insulin during OGTT than female subjects ($p < 0.001$ for glucose and $p = 0.005$ for insulin by repeated measure ANOVA).

The numerical data of Figure 2.

Male (n=42)

	0 (min)	30	60	90	120	180
Plasma glucose (mg/dl)	5.208 (0.3695)	8.579 (1.272)	7.167 (1.824)	6.262 (1.523)	5.749 (1.102)	4.360 (1.205)
Insulin (microU/ml)	6.057 (3.519)	64.95 (64.53)	53.70 (47.86)	53.27 (49.61)	49.84 (50.66)	20.94 (24.37)

Female (n=69)

	0 (min)	30	60	90	120	180
Plasma glucose (mg/dl)	4.930 (0.4266)	7.529 (1.460)	6.596 (1.946)	6.178 (1.541)	5.829 (1.487)	4.881 (1.121)
Insulin (microU/ml)	7.090 (5.107)	66.22 (42.62)	57.09 (51.97)	54.95 (44.39)	51.11 (39.85)	31.82 (28.03)

Data are expressed as mean (SD).

Figure 1. Flow of Participants through the study.






Figure 2. The gender differences of glucose and insulin levels during OGTT in young adults with very low birth weight (VLBW).



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	n/a
Bias	9	Describe any efforts to address potential sources of bias	18
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-12
		(b) Describe any methods used to examine subgroups and interactions	13
		(c) Explain how missing data were addressed	n/a
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	n/a
Outcome data	15*	Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-14
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14
Discussion			
Key results	18	Summarise key results with reference to study objectives	14-15
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	17-18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.